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A bstract.
In recent years the idea that resistance to some or all of the normal biological 
actions o f insulin may be one of the root causes of several conditions, among them 
essential hypertension, has come to the fore. Moreover, although most drugs 
currently used in the treatment of essential hypertension do not appear to address this 
problem, one group, the angiotensin converting enzyme (ACE) inhibitors, does seem 
so to do.
The aim of this project was to investigate a small animal model of insulin 
resistance (based on an intravenous glucose tolerance test) and to use this model to 
test the assertion that ACE inhibitors are indeed able to modify insulin sensitivity. This 
was followed up with studies in vitro (measuring glucose uptake by the rat 
hemidiaphragm) to complement the in vivo results. A study of a possible link between 
plasma glucose and K+ concentrations was also undertaken in vivo.
When compared with normotensive rats, spontaneously hypertensive rats 
(SHRs) showed little evidence of being insulin resistant in vivo. Only captopril, of the 
ACE inhibitors tested, had any effect on glucose tolerance, worsening it significantly. 
Epicaptopril and losartan also worsened glucose tolerance, but L-cysteine did not.
The hemidiaphragms of SHRs did not show any signs of insulin resistance in 
vitro, but captopril, at one of the concentrations tested, significantly reduced glucose 
uptake, mimicking its in vivo effect.
It was concluded, therefore, that glucose intolerance is not a property of 
skeletal muscle itself in the SHR, and that the whole animal is not insulin resistant. 
Captopril worsens glucose tolerance in the SHR, possibly by inhibiting the formation 
of angiotensin II by a specific ACE. It was concluded from the study of plasma 
glucose and K+ concentrations that although the link between the two was weak, it
was, nevertheless, present. The results also indicated that there was a constitutively 
higher activation of Na+/K+ ATPase in the SHR than in Wistar rats.
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Blood pressure, in the normal course of events, increases with age. In a 
healthy individual this increase represents no threat, even in old age, when systolic 
blood pressure may be twice what it was at birth. The control of blood pressure is 
finely regulated by a complex interplay of systems so that from minute to minute, or 
year to year, this most important o f homeostatic mechanisms ensures a good blood 
supply to all parts of the body.
The blood pressure o f an organism is dependent on two factors - cardiac 
output (CO) and total peripheral resistance (TPR), which are commonly linked in the 
formula
BP = CO x TPR.
In healthy individuals an increase in CO would result in a reflex reduction of 
TPR in order to maintain a steady blood pressure, and vice versa. In the short term 
this is carried out mainly by neuronal mechanisms. Humoral regulation of blood 
pressure is generally concerned with the longer term and more gradual control of 
homeostasis.
The most important mechanism responsible for the maintenance of blood 
pressure over short time periods (a few seconds) is the baroreceptor reflex. The 
baroreceptors are located around the aortic arch and carotid sinuses and are essentially 
stretch receptors which increase their rate of firing with increases in blood pressure. 
Activation of the baroreceptors results in a centrally co-ordinated alteration of the 
balance of cardiovascular sympathetic and parasympathetic activity in favour of the 
parasympathetic. The major consequence of this is the reduction of sympathetic- 
driven vasoconstriction, and secondarily a fall in CO, caused by both a reduction of 
sympathetic activity and stimulation of the vagal input to the heart. The baroreceptor
2
reflex works to a "set point" system, altering its activity to correspond with the size of 
departure from that set point (Levy, 1990).
Similarly placed around the aortic arch and carotid sinuses are the 
chemoreceptors. These are stimulated by a reduction in blood oxygen content and pH, 
and an increase in blood C 0 2 content. The main effect of their stimulation is the 
activation o f a reflex which increases pulmonary ventilation, but a secondary effect is 
to induce bradycardia and peripheral vasoconstriction (Levy, 1990).
While most humoral mechanisms work in the longer term, some do operate 
over short time scales. The prime examples o f these are the endothelium-derived 
mediators nitric oxide (Palmer et al., 1987), the prostaglandins (Smith, 1986), and the 
endothelins (Anggard et al., 1990). While these do affect blood pressure, it seems 
more likely, given their ubiquitous presence and short half-lives, that they act more as 
local regulators of blood flow than systemic regulators of pressure.
Although neural mechanisms do not play a major role in the longer term 
control of blood pressure, they are important in several ways. For example, 
sympathetic stimulation is one o f the stimuli responsible for the release o f renin from 
the juxtaglomerular apparatus in the kidney (Opie, 1992), and chronic stress is known 
to lead to elevated catecholamine levels in the blood and can be a factor in the 
development of hypertension (Herd, 1984).
It is the humoral systems of the body which are responsible for the general 
maintenance of vascular tone, on top of which the short term systems exert a fine 
tuning influence. One of the most important of these humoral mechanisms is the renin- 
angiotensin-aldosterone system, which will be covered in more depth later on. This 
system, through its action on the kidney, helps regulate the body's electrolyte content 
(Opie, 1992), and through the production of angiotensin II both in the plasma and the
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vessel walls (for which there is now good evidence (Dzau, 1993)) maintains vascular 
tone (Lee et al., 1992). Moreover, production of angiotensin II in the brain stimulates 
the drinking response in experimental animals. Several other compounds also act on 
the kidney. Those which stimulate Na+ or water loss include atrial natriuretic peptide 
which is released from the right atrium in response to an increase in atrial filling, and 
inhibits water and Na+ resorption in the nephron as well as inhibiting renin release and 
antagonising angiotensin II- and noradrenaline-induced vasoconstriction. This latter 
group also includes the kinins since a fully competent kinin system has been observed 
in the kidney which has both a natriuretic and diuretic action (Oparil and Katholi,
1990).
The control of blood pressure is therefore dependent upon the successful 
integration o f short and long term mechanisms to control CO, TPR, and blood 
volume.
In many people, however, the control of blood pressure is less exact than in 
subjects which one might consider "normal". Some individuals' blood pressures are 
too low, which has its own complications, but in the vast majority of people with poor 
control, approximately 30% of the population (Ceriello et al., 1993), blood pressure 
tends to creep up too quickly, rather than fail to rise at all. A patient is usually said to 
have hypertension if he or she has a diastolic blood pressure o f greater than 95mmHg, 
although this figure is variable since blood pressure increases with age anyway. Thus a 
diastolic pressure o f lOOmmHg is considered much more serious in a person who is 
twenty years old than in one who is eighty.
Hypertension brings with it some well known risks, besides the detrimental 
effects of high blood pressure (such as glomerulonephropathy) per se. These include 
an increased risk o f suffering a stroke, myocardial infarction, heart failure, other
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thromboembolic episodes, blindness due to damage to the retina, and atherosclerosis. 
The result is that cardiovascular disease of one form or another is responsible for the 
greatest single number of deaths each year in Britain.
The causes of essential hypertension (as opposed to "secondary hypertension" 
which describes those forms o f the condition for which a definite cause can be 
identified) are undoubtedly complex, and many different hypotheses have been put 
forward to explain the fundamental dysfunctions of the condition. These have 
variously suggested the involvement of the peripheral and central nervous systems, 
growth factors, electrolyte imbalance, genetic factors, environmental causes, and 
hormonal influences. It seems certain that some, or possibly all, of these theories are 
involved in the loss of good blood pressure regulation. This thesis will concentrate on 
some aspects o f the roles of hormones and electrolytes in the aetiology of essential 
hypertension and generally will not be concerned with high blood pressure o f known 
causes.
Much recent speculation has revolved around the possibility that one o f the 
major problems in essential hypertension may be a resistance to the normal ability of 
insulin to reduce the concentration of glucose in the plasma (Reaven, 1988). 
Certainly, abnormally high concentrations of insulin have been observed in the plasma 
of essential hypertensives (Ferrannini et al., 1987), some of the consequences o f which 
might be to increase blood pressure. The mechanisms by which this could occur are 
presented in a later part of this introduction, but first the mode of action o f insulin 
under normal conditions will be discussed.
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Insulin - mode of action.
Insulin was discovered in 1922 by Banting, Best, Macleod and Collip in 
Toronto. In 1955 it was the first protein to be sequenced completely. These two 
breakthroughs gained their originators two Nobel prizes, but, in spite of the wealth of 
information which has now been accumulated, surprisingly little is actually known 
about how insulin works.
To the endocrinologist the classic function o f insulin is as the primary mediator 
o f glucose disposal in the body, and, in concert with glucagon, it is indispensably 
involved in the regulation of blood glucose levels. This, however, is not all. Insulin 
also stimulates amino acid and ion uptake, serine and tyrosine phosphorylation of a 
multitude o f cellular proteins, the suppression of lipolysis, the inhibition of intracellular 
free fatty acid oxidation, the stimulation, or suppression, of transcription o f certain 
genes, and the promotion of cell growth and expression o f oncogenes (for review see 
Seino et al., 1990). So important is it, that virtually all cells in the mammalian body 
can respond to the presence of insulin (Kahn and White, 1988).
Many substances alter the release of insulin from the |3 cells of the islets of 
Langerhans in the pancreas. The most important of these, and the only one able to 
stimulate insulin release on its own, is glucose (Espinal, 1989). All other compounds 
which modulate insulin secretion require the simultaneous presence of glucose. Indeed 
the prevailing concentration of plasma glucose is important in determining the 
stimulation of insulin secretion by non-glucose secretagogues. Increases in plasma 
glucose concentration result in a greater insulin response to, for example, arginine, a 
phenomenon known as "glucose potentiation" (Pfeifer and Broadstone, 1991). The 
non-glucose compounds which modulate insulin release include amino acids, fatty 
acids, sympathetic stimulation through (3 adrenoceptors, cholinergic stimulation, and
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several hormones (secretin, gastrin, gastric inhibitory polypeptide, and 
cholecystokinin) (Pfeifer and Broadstone, 1991). Other factors reduce glucose-
stimulated insulin secretion, in particular the other islet hormones glucagon and 
somatostatin, but also serotonin, and noradrenaline working through a  adrenoceptors 
on the (3 cells (Espinal, 1989).
When insulin stimulates glucose uptake, by far the largest proportion of the 
glucose is taken up into the skeletal muscle mass. In man, this proportion has been 
estimated to be approximately 85% of total insulin-stimulated glucose metabolism (De 
Fronzo et al., 1981), another 8% being removed by the splanchnic region (Ferrannini 
et al., 1987). Skeletal muscle is also by far the most insulin-sensitive tissue in rats 
(James et al., 1985), accounting for more than 90% of insulin-stimulated glucose 
disposal (Kraegen et al., 1985). The other insulin-sensitive tissues in this species 
include adipose tissue, heart, and lung. The liver, brain, and other organs (e.g. kidney, 
spleen, pancreas) are not sensitive to the ability of insulin to promote glucose uptake, 
and together with adipose tissue, the heart, and the lung account for less than 10% of 
the glucose uptake o f an intravenous load (Kraegen et al., 1985).
Circulating insulin mediates its effects through the insulin receptor - the 
product of a gene found near the end of the short arm of chromosome 19. The 22 
exon gene codes for an a - (3 subunit dimer, two of which are linked by a disulphide 
bridge between the two a  subunits to make the active receptor (figure I I ) .  Exon 11 
may be omitted during the splicing process which produces the translatable messenger 
RNA (mRNA), thus producing an a  subunit which is smaller by 12 amino acids than 
the unspliced alternative. The receptor with the larger a  subunit is known as the type 
B receptor, and that with the smaller one is type A (Yarden and Ullrich, 1988). The 
3brain and spleen express type B subunit almost exclusively, whereas the other tissues 
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Figu re  I 1, Diagram to show the subunit structure o f  the insulin receptor and some 
important points o f  the primary amino acid sequence.
Kev.
K (=KDa) - molecular mass of the subunit; Tyr-1 lxx - position in the primary' amino 
acid sequence of  a tyrosine residue which is phosphorylated on stimulation of the 
receptor by insulin; -S-S- disulphide bridge linking two subunits; Lys-1018 - lysine 
residue in position 1018 in the primary amino acid sequence, thought to be important 
for ATP binding.
References.
Insulin binding site: Carpentier, 1989; Yip et a l ., 1990.
Molecular mass, disulphide bridges: Carpentier, 1989.
ATP binding site: Kahn and White, 1988.
Tyrosine autophosphorylation sites: Zhang et al., 1991; Sung, 1992.
Stimulation o f the receptor by insulin activates the (3 subunit which is able to 
autophosphorylate, and phosphorylate other proteins, on tyrosine residues (Zhang et 
a l, 1991). There is, in addition, good evidence that, through the insulin receptor, 
insulin is able to activate at least one (Eckel et al., 1990; Kellerer et al., 1991; 
Mortensen et al., 1992) and possibly two (Kahn and White, 1988) G-proteins, and that 
a protein known as "insulin receptor substrate 1" (IRS-1) interacts with the insulin 
bound receptor to cause several intracellular changes (Sun et al., 1991; Shoelson et 
al., 1992). Through the activation o f the oncogene product p21ras insulin also appears 
to be able to stimulate gene expression (Burgering et al., 1991). This is by no means 
an exhaustive list o f the first steps o f insulin signalling. Figure I 2 gives an idea of the 
complexity of insulin's intracellular influences.
The ultimate consequences of insulin stimulation of a cell must be equally 
convoluted. At the plasma membrane the classic cellular response is the translocation 
o f glucose transporters from intracellular stores to the cell membrane (Bomemann et 
al., 1992; Pessin and Bell, 1992). Na+/H+ antiport activity is also stimulated by insulin 
(Vara and Rozengurt, 1985) as is the translocation to the plasma membrane of an a  
and (3 subunit pair o f the Na+/K+ ATPase in both the frog (Omatsu-Kanbe and 
Kitasato, 1990) and the rat (Hundal et al., 1992). Intracellularly, this almost 
omnipotent hormone sets off a cascade of phosphorylation and dephosphorylation 
reactions, the consequences of which include stimulation of glycogen synthase and 
pyruvate dehydrogenase (Roach, 1990; Lawrence, 1992). It is due to these highly 
complex interactions that the pathways through which insulin has effects such as the 
stimulation of glucose and amino acid uptake still remain uncertain.
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Figure I 2. Diagram showing some o f  the intracellular pathways by which insulin influences cellular 
ionic balance and glucose storage as glycogen. (Insulin also stimulates glycolysis and inhibits 
lipolysis).
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Key. AC - adenylate cyclase; DAG - diacylglycerol; cAMP-PK - cAMP-dependent protein kinase; CKI - casein 
kinase I; Gj - G protein which inhibits AC; Gs - G protein which stimulates AC; GLUT4 - insulin-responsive 
glucose transporter; GP - glycogen phosphorylase; G-6-P - glucose-6-phosphate; GS - glycogen synthase; GSK-3 - 
glycogen synthase kinase 3; GSP - glycogen synthase phosphatase; IRS-1 - insulin receptor substrate 1; ISPK - 
insulin-stimulated protein kinase; MAP2 kinase - microtubule associated protein 2 kinase; MFPK - multifunctional 
protein kinase; - phosphorylated form of the protein; PK - phosphorylase kinase; PLC - phospholipase C; Gjns
- insulin-specific G protein; PP1G - protein phosphatase 1 (glycogen type); PKC - protein kinase C; PTPP - 
phosphotyrosyl protein phosphatase; Rj - receptor which interacts with Gj; Rs - receptor which interacts with Gs.
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Extracellular
Evidence for insulin resistance.
With so many reactions triggered by the arrival o f insulin at the cell surface, it 
is not surprising that there is room for the system to falter on occasion. It has been 
known for some time that certain people are resistant to the normal hypoglycaemic 
action of insulin, which is manifest clinically as a reduced rate of clearance of a glucose 
load. This has been observed in patients with both type 2 (non insulin-dependent) 
diabetes mellitus and those who are obese (Modan et al., 1985; Reaven, 1988). Since 
the mid-1980s an idea which has gained increasing credibility is that essential 
hypertension should be included with obesity and type 2 diabetes when talking about 
insulin resistance. The occurrence o f the three conditions overlaps so much (Modan et 
al., 1985; Ferrannini et al., 1990) that a common cause or influence could be a factor 
in their aetiology. In this respect many studies have now shown that insulin resistance 
occurs in hypertensives independently o f obesity or type 2 diabetes (Modan et al., 
1985; Ferrannini et al., 1987). Nor is this a trivial finding. Using the 
hyperinsulinaemic, euglycaemic clamp technique in which insulin is infused into a 
subject at a constant rate and a simultaneous infusion of glucose is varied to maintain a 
constant plasma glucose concentration (De Fronzo et a l, 1979), Ferrannini and 
colleagues (1987) showed that hypertensives were able to clear glucose from the 
blood 40% less quickly than normotensives at the rate of insulin infusion used. 
Similarly, the insulin sensitivity index (a measure o f the ability of each unit o f insulin in 
a patient's plasma to lower plasma glucose concentration) in a group of 194 subjects 
was 19% lower than normal in the subgroup which were hypertensive, and 46% lower 
than normal in the group which were obese as well as hypertensive (Lithell et al.,
1990).
Although the three conditions are all characterised by the presence of insulin 
resistance, there are differences other than the clinically observed endpoints of
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hypertension, obesity or type 2 diabetes (Ferrannini et al., 1987). A summary by these 
authors o f metabolic changes in the three conditions showed interesting "variations on 
a theme". All three diseases incorporate a reduced whole body glucose uptake rate 
and decreased non oxidative glucose disposal. Hypertension showed no further 
complications, unlike type 2 diabetes where glucose oxidation and suppression of 
lipolysis were both compromised, and obesity which showed reduced suppression of 
glucose output and less effective promotion of K+ uptake while lipid oxidation was 
increased (suppression o f lipolysis was normal). On the one hand this may suggest 
that insulin resistance is a root cause of all three conditions, and the clinical outcome 
depends on the presence or absence of other genetic or environmental factors. 
Conversely, however, the different metabolic disorders may be different routes to the 
same end - insulin resistance - which has resulted in an incorrect association of the 
three conditions (Ferrari and Weidmann, 1990). Care must therefore be taken when 
extrapolating results from studies of one disease to considerations of another. 
Unfortunately the hand o f the investigator of this aspect of essential hypertension is 
somewhat forced since most o f the data on insulin resistance collected so far refer to 
type 2 diabetes and obesity. It is necessary, therefore, to take a calculated risk based 
upon the evidence o f similarity, and make such extrapolations. The most widely 
accepted case is that the three diseases have a common cause. One can see, therefore, 
that essential hypertension appears to represent the simplest case of insulin resistance, 
and as such could offer a unique opportunity to study the root cause of the disorder 
without too many comp heating factors.
As a result o f the conflicting data produced by experiments with humans, other 
researchers have turned to animal models of essential hypertension to address the 
problem. An early study by Yamori and co-workers (1978) showed the stroke prone 
spontaneously hypertensive rats (SHRs) exhibited a raised basal plasma glucose
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concentration, and a greater increase in plasma glucose concentration during an 
intravenous glucose tolerance test compared with Wistar Kyoto (WKY) controls, 
while insulin concentrations were no different. In contrast, in another study glucose 
concentrations during an oral glucose tolerance test were similar in SHRs and WKY 
rats, but insulin concentrations were higher in the hypertensive strain (Mondon and 
Reaven, 1988). These early findings suggested that SHRs are insulin resistant. 
However, as the more sophisticated hyperinsulinaemic euglycaemic clamp technique 
has become more widely used, other studies have failed to show the same trends. 
Hulman and colleagues (1991) were unable to provide evidence of insulin resistance in 
SHRs compared with WKY rats, and both Gaboury and associates (1991) and 
Frontoni and co-workers (1992) found evidence that the WKY rat is less sensitive to 
insulin than the SHR. In particular, during an intravenous glucose tolerance test the 
area under the glucose extinction curve was greater in WKY rats than in SHRs, and 
during an oral glucose tolerance test the same was true of the insulin response curve 
(Gaboury et al., 1991). Moreover, at submaximal plasma insulin concentrations 
during a clamp experiment, the rates o f glucose uptake and glycogen synthesis were 
1.5 and 1.8 times greater in SHRs than WKY rats (Frontoni et al., 1992). The most 
recent results, however, do appear to show insulin resistance using the insulin clamp 
technique (Rao, 1993). In this investigation, the relationship of plasma insulin 
concentration to glucose disposal rate showed very significant insulin resistance in 
SHRs. In the SHR, therefore, it is not yet firmly established that insulin resistance 
exists, and more work needs to be done to find out whether the SHR represents a 
good model o f human insulin resistance.
It has become one of the established tenets of this area of research that the 
resistance is almost entirely due to a reduction o f skeletal muscle glucose uptake, in 
itself a result o f a lower flux through the glycogen synthesising system (Cusin et al.,
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1990; Ferrannini et al., 1987; Haring and Mehnert, 1993). Other tissues may also 
contribute to insulin resistance, in particular white adipose tissue (WAT), but estimates 
o f the importance of WAT vary widely. Adipocytes from SHRs have been shown to 
be insulin resistant in vitro (Reaven et al., 1989) as have those of patients with type 2 
diabetes (Kashiwagi et al., 1983) and those from Sprague-Dawley rats fed on a high 
fat diet, another recognised route to whole body insulin resistance (Pedersen et al.,
1991). In contrast, Cusin and co-workers (1990) caused the opposite effect in rats 
which were infused with insulin for four days to induce hyperinsulinaemia, as did 
Takao and colleagues (1990) when they induced hyperglycaemia in rats for four days. 
Current research therefore tends to concentrate on skeletal muscle as the likely site of 
insulin resistance. This is because it is by far the largest glucose sink, and because it is 
the largest o f the three main insulin-responsive tissues and as such has the greatest 
potential for causing the substantial decreases in insulin-stimulated glucose uptake 
which have been observed.
The case for the existence of insulin resistance in essential hypertension is not 
absolute, though. One study, especially, was unable to find insulin resistance in 
essential hypertensives for which obesity or type 2 diabetes did not provide an 
adequate explanation (Bonora et al., 1993). In this study five groups of subjects were 
used: lean, non-hypertensive non-diabetic controls, obese subjects, obese subjects with 
hypertension, type 2 diabetic subjects, and type 2 diabetic subjects with hypertension. 
Compared with the controls, the obese and diabetic groups were insulin resistant. 
However, in neither disease did simultaneous hypertension appear to cause a further 
worsening o f insulin resistance. As well as implying that insulin resistance and 
essential hypertension are not causally linked, this study also illustrates the great 
importance o f controlling experiments for the confounding factors of type 2 diabetes 
and obesity, which can cause up to a 50% reduction in insulin-stimulated glucose
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uptake in their own right (Bonora et al., 1993).
Causes of insulin resistance.
The evidence in favour of a role for insulin resistance in the aetiology of 
essential hypertension, as well as type 2 diabetes and obesity, seems convincing, and 
certainly worth further investigation. The cause of insulin resistance itself, however, is 
still more or less a complete mystery. This is perhaps not surprising given the number 
o f elements involved in the insulin signalling pathways. The only way to be sure of 
finding the fundamental fault within the cell is to sequence every protein involved in 
any way with insulin, and determine which of these has or have an altered sequence or 
processing. Unfortunately, this is impractical since it would involve an inordinate cost 
in personnel and resources. The human genome project aims to sequence all 23 
chromosomes, but even when this has been done most of the genes so discovered will 
be of unknown function for a long time afterwards.
There is good evidence that this approach would turn up some valuable 
answers. This evidence comes from studies of monozygotic twins suffering from type 
2 diabetes or from family histories of type 2 diabetics such as that o f Cook and 
associates (1993). These workers concluded that type 2 diabetes is likely to occur in 
response to the inheritance of several genes, which is a similar finding to that of the 
many investigations of genetic causes of essential hypertension. With direct reference 
to essential hypertension in humans, Lever and Harrapp (1992) have suggested that 
the influence of genetic make-up on blood pressure is approximately twice as strong as 
environmental influence.
Investigations o f the actual genes which co-segregate with essential 
hypertension have been carried out in animals The number of genes involved in
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essential hypertension is thought to be small - two to three major ones plus some less 
important loci (Lindpainter et a l ,  1990). Currently about six different genes have 
been imp heated in the hypertension seen in SHRs (Ganten et al., 1991; Jacob et al., 
1991; Nara et al., 1991; Nabika et a l,  1993; Hilbert et a l ,  1991). However, since the 
functions o f these genes are unknown (except in the cases of Lindpainter and 
colleagues (1990) where a mutation of the renin gene of the stroke-prone SHR 
(SHRSP) was identified, and Nara and co-workers (1991) who demonstrated that 
angiotensin converting enzyme (ACE) in the SHRSP was different from the WKY rat 
version), and since the signalling pathways are incompletely understood, an 
"experimental" (as opposed to "observational") approach to dissecting out the causes 
o f insulin resistance must be adopted.
The most obvious place to start is with the insulin receptor. Although Mosthaf 
and colleagues (1991) found that the type B (low affinity) receptor mRNA was 
expressed at levels equivalent to 50-100% of those o f the type A receptor mRNA in 
skeletal muscle from type 2 diabetics compared with tissue from normal subjects, 
which express only type A receptor mRNA, most reports have found no alteration of 
receptor affinity or activity. Thus insulin binding was normal in insulin resistant 
adipocytes from type 2 diabetics (Kashiwagi et a l ,  1983), and total receptor number, 
affinity and tyrosine kinase activity (as estimated by the ability of partially purified 
receptors to phosphorylate poly-(Glu.Tyr)) were similar in SHR and WKY rat 
adipocytes (Reaven et a l,  1989). In addition, the latter study also revealed similar 
basal and maximal (insulin-stimulated) tyrosine kinase activities with similar 
sensitivities. Where insulin receptor number has been found to be reduced in several 
tissues, estimates have suggested that this is not enough to account for the whole of 
the insulin resistance in the patients in question (Moller and Flier, 1991).
If insulin receptor number and function is unaffected by insulin resistance,
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perhaps the same is not the case for the expression of active glucose transporters at 
the cell surface. In both fat and muscle the insulin-responsive glucose transporter is 
GLUT4, one o f five glucose transporter types so far characterised in man and rat (for 
review see Pessin and Bell, 1992). Measurements o f GLUT4 and GLUT4 mRNA 
showed that there was no difference which could explain insulin resistance between 
normals and type 2 diabetics with respect to these parameters (Eriksson et al., 1992a). 
Indeed, there was an over-expression of GLUT4 mRNA in subjects with diabetes.
Results in experiments where hyperinsulinaemia has been artificially induced 
are somewhat contradictory. Infusion of 60mg.Kg'kmin_1 glucose into Sprague- 
Dawley rats for three days induces a hyperinsulinaemia associated with an increase of 
GLUT4 mRNA of approximately 200% but no increase in GLUT4 protein (Hager et 
al., 1991). This mimics the human situation. However, feeding rats with a high fat 
diet induced hypoinsulinaemia with insulin resistance that stemmed from a reduction in 
GLUT4 protein in the adipocyte membrane (Pedersen et al., 1991). In another study 
it was shown that four days of hyperinsulinaemia in lean Zucker rats was able to 
increase GLUT4 mRNA expression in adipocytes by about fifteen-fold while reducing 
its expression in diaphragm and tibialis muscle by approximately 60% (Cusin et al.,
1990). Clearly the results obtained are highly dependent upon species, tissue, and the 
method o f achieving insulin resistance. The consensus is that in the human a reduction 
in GLUT4 number or function in the plasma membrane is not a major contributor to 
insulin resistance (Moller and Flier, 1991). Nor is it necessary that one should be. In 
a study of the mechanics of glucose transport and metabolism, Furler and colleagues 
(1991) were able to show that glucose transport into the cell is the rate limiting step of 
glucose metabolism under normal conditions. When brain and red muscle are under 
conditions of maximal glucose metabolism, however, the rate limiting step moves 
towards the phosphorylation of glucose. This illustrates the potential for the slightest
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defect in a glucose-processing enzyme to cause insulin resistance by altering the 
position o f the rate limiting step of glucose metabolism. There is, in fact, good 
evidence that glycogen synthase (GS) is just such an enzyme (Ferrannini et al., 1990). 
The findings of Bak and colleagues (1992), namely that in type 2 diabetes levels of GS 
in vastus lateralis muscle were normal but that its activation by insulin was markedly 
reduced, are complemented by a series o f studies carried out by Beck-Nielsen's group. 
These investigators also showed that type 2 diabetes and obesity separately affect GS 
activity by reducing its insulin-stimulated activation while not actually having any 
effect on allosteric activation of the enzyme by glucose-6-phosphate (Damsbo et al.,
1991). Very similar results were found in first degree relatives o f type 2 diabetics 
(Vaag et al., 1992a) where the insulin resistance was shown to correlate positively 
with a defect in GS activation. The same group additionally demonstrated that the 
hyperglycaemia associated with insulin resistance overcomes the resistance in skeletal 
muscle by acting in a permissive role to allow greater stimulation of GS by insulin. 
Thus basal GS flux is similar in normals and diabetics, but the diabetics need the 
greater stimulus to achieve parity (Vaag et al., 1992b).
It is probable, therefore, that the control of GS and other enzymes is faulty. It 
seems unlikely that this is caused by an inhibitory factor at the level o f the insulin 
receptor, as Sbraccia and colleagues (1991) found in their study of a particular patient 
with type 2 diabetes and insulin resistance, since other reports conclude that tyrosine 
kinase activity (Reaven et al., 1989; Groop et al., 1991; Bak et al.. 1992) and insulin 
binding to its receptor (Kashgiwagi et al., 1983) are normal. A more likely candidate 
is a protein kinase or phosphatase in the insulin signalling cascade. The activity of 
protein tyrosine phosphatase (PTPase), which dephosphorylates tyrosine residues, is 
inadequately suppressed by insulin in skeletal muscle of diabetics (McGuire et al.,
1991). This would dampen down the effects of insulin signalling through tyrosine
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phosphorylation. Phosphorylase phosphatase is an enzyme which activates GS. Its 
activity in quadriceps femoris muscle was shown to be reduced by approximately 25% 
in insulin resistant man (Kida et al., 1992) which could account for the defect in GS 
activity in the condition. On the other hand, it could equally well be the activation of 
phosphorylase phosphatase which is abnormal. These examples serve as clues to 
possible intracellular causes o f insulin resistance, but need confirmation by other 
workers and by other approaches.
Disturbed ionic balance across the plasma membrane is often thought to be a 
consequence of insulin resistance, but there is evidence that it may be a cause of it. 
Magnesium (Mg4-4-) has received some attention in this respect, particularly since it is 
known that type 2 diabetes is associated with Mg4-4 depletion of the plasma and 
erythrocytes (Paolisso et al., 1990). Several glucose metabolising enzymes require 
Mg44- as a cofactor, and erythrocytes from essential hypertensives have an impaired 
ability to accumulate Mg4-4 (Paolisso et al., 1990). Especially interesting is the fact 
that abnormalities o f Mg4-4- handling occur very early in the development of diabetes 
(Paolisso et al., 1990). Calcium (Ca4^ )  has also received some attention. The 
concentration of Ca++ in platelets has been found to correlate negatively with insulin 
sensitivity and to be an early marker of it in normotensive offspring with a family 
history of essential hypertension (Ohno et al., 1993). The mechanism by which 
impaired Ca-44 homeostasis could cause insulin resistance is unknown, but could 
conceivably work through activation of enzymes which inhibit the action of insulin.
Another normal physiological response to insulin is an increase in blood flow 
through skeletal muscle (Gans, 1992). Once again the efficacy of insulin in causing 
this reaction appears to be reduced in insulin resistance (Laasko et al., 1992). Clearly, 
if the normal increase in blood flow in response to insulin is lacking in type 2 diabetes 
and obese subjects, insulin resistance may be due in part to a reduced delivery of
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substrate to the glucose transporters.
In theory, then, there are many opportunities for insulin resistance to develop 
within the cell. A factor under genetic control is not, though, the only way to cause 
insulin resistance. The over-production of a physiological factor could also reduce the 
sensitivity o f the body to insulin. One such factor is amylin (or islet amyloid 
polypeptide).
Amyloid deposits are a well known feature of the islets of Langerhans in type 2 
diabetic patients. They occur in the p cells of the islets and contain large quantities of 
the 37 amino acid peptide amylin. Synthetic amylin has been shown to reduce insulin- 
stimulated glucose uptake and GS activity in rat skeletal muscle (Cooper et al., 1988) 
and similar results have been obtained with native amylin (Leighton and Cooper, 
1988). Frontoni and co-workers (1991) have also shown that GS activity is reduced 
in rats infused with amylin. In their study this reduction amounted to 77% in soleus 
muscle. The results have been extended to rat diaphragm, where amylin caused a 60% 
reduction in insulin-stimulated glucose uptake (Hothersall et al., 1990). A second 
action of amylin is the ability to stimulate glycogenolysis. In fact it is reported to be 
more potent and more effective in this respect than glucagon (Wang et al., 1991).
These reports would be convincing were it not for the fact that they were all 
carried out with very high levels o f amylin (10_9M upwards). Physiological levels of 
the polypeptide in vivo are closer to 10_l4M (Eriksson et al., 1992b), and 
concentrations as high as 10*10M have no discernible effect in vitro (Zierath et al,
1992). Erikson and colleagues (1992) did, however, make the observation that the 
release of amylin into the plasma of glucose-intolerant first degree relatives of type 2 
diabetics was greater than in normals or in glucose tolerant relatives. Perhaps in the 
longer term less amylin is required to induce insulin resistance than in the acute
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experiments reviewed here.
There are also several other factors which have the potential to reduce insulin 
sensitivity, o f skeletal muscle in particular. Glucocorticoids, for example are 
constantly present in the blood, and the inhibition of their effects with the 
glucocorticoid receptor antagonist RU 486 has been shown to increase the sensitivity 
o f tissues to insulin (Leighton et al., 1991). Furthermore, the administration of a 
glucocorticoid, dexamethasone, to rats is well known to raise blood pressure and 
induce insulin resistance (Yin et al., 1992). Glucagon, present at raised concentrations 
in the blood o f type 2 diabetics (Lefebvre, 1991) and released in excess in response to 
stimulation o f a  cells with arginine in similar patients (Hamaguchi et al., 1991), 
provides classical functional antagonism to the action of insulin. Gastric inhibitory 
polypeptide has also been shown to have the capacity to reduce the insulin sensitivity 
o f muscle in rats (Dupre, 1991) and is found to be increased in obese humans (Dupre, 
1991). Finally, adrenaline is also capable of acting similarly to glucagon in that it 
inhibits skeletal muscle glycogenesis and promotes glycogen breakdown by muscle and 
liver (Christopher et al., 1992) and is present in increased amounts in the SHR 
(Frontoni et al., 1992).
The data reviewed here therefore indicate that there are several approaches to 
investigating the causes o f insulin resistance which are under consideration in the 
scientific community, and that, besides the fact that the cause is probably a 
modification o f insulin signalling at a point beyond the insulin receptor, little progress 
has been made towards finding out what makes the majority of patients insulin 
resistant.
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Consequences of insulin resistance.
There are two immediately apparent consequences of insulin resistance. These 
are hyperglycaemia, and, in order to try to compensate for this, over-secretion of 
insulin by the (3 cells leading to hyperinsulinaemia. These are the two most frequently 
measured parameters o f insulin resistance.
The increase in plasma glucose may itself be a risk factor which exacerbates 
insulin resistance. The production of oxygen free radicals through, for example, 
glycation of proteins could compromise endothelial cell functions such as the 
production of endothelium derived relaxant factor (Ceriello et al., 1993). Within the 
cell, at least in rat adipocytes, glucose has been reported to increase insulin binding to 
its receptor, and the sensitivity of the glucose transport response (Traxinger and 
Marshall, 1990). In contrast, other experiments, also carried out in rat adipocytes, 
have led to the opposite conclusion. Incubation of adipocytes with insulin, glucose, or 
both over 24 hours caused a marked reduction in glucose uptake in response to a dose 
o f insulin. The ED50 value o f insulin was raised by 183% when cells had been pre­
incubated with both insulin and glucose (Lima et al., 1991). Clearly these data conflict 
with one another and are therefore inconclusive. They do show, though, that glucose 
can have an effect of its own on its target cells, and is not just a source of energy.
Hyperinsulinaemia is more likely, however, to be the main offender in the 
scenario, although once again the evidence is not absolute. One can hypothesise many 
routes by which hyperinsulinaemia might cause hypertension (some of which will be 
dealt with hereafter) and much o f the evidence collected from investigations support 
elements of these hypotheses. However, it has proven difficult to show that 
hyperinsulinaemia does cause hypertension. Brands and colleagues (1991) have had 
some success. They caused hypertension (an increase of 8mmHg) in Sprague-Dawley
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rats by infusing insulin for five days at a rate which caused moderate 
hyperinsulinaemia. These data are contradicted by other findings, though. In a study 
of patients with confirmed insulinomas, and consequent hyperinsulinaemia, Pontiroli 
and co-workers (1992) were unable to find any correlation between blood insulin 
concentration and blood pressure, even though insulin concentration did correlate with 
insulin resistance. In SHRs, while one report has provided evidence for 
hyperinsulinaemia (compared with WKY rats) (Mondon and Reaven, 1988), another 
(Buchanan et al., 1992) has shown hypertension without insulin resistance in the same 
strain of rat. These latter studies illustrate that though the SHR is probably regarded 
as the best model of human essential hypertension to date, its similarity to the human 
condition cannot be taken for granted and it is still being assessed with respect to 
insulin resistance and the consequences thereof.
One of the mechanisms by which hyperinsulinaemia may cause hypertension is 
very simple. The various arms o f insulin signalling are largely separate (Ferrannini et 
al., 1988). If it is only glucose metabolism that becomes resistant, the resulting 
hyperinsulinaemia will over-stimulate other branches of the insulin signalling cascade. 
For example, one might expect to see over-stimulation of Na+/K+ ATPase.
A variety of approaches have provided data which imply an ability of insulin to 
raise blood pressure including the augmentation of sympathetic nervous system (SNS) 
activity, the stimulation of vascular smooth muscle cell (VSMC) hypertrophy and 
hyperplasia, the alteration of blood flow, and the stimulation of certain ionic 
homeostatic mechanisms.
Both in normal humans (Gans et al., 1991b) and in rat isolated mesenteric beds 
(Townsend et al., 1992) the pressor activity o f exogenous NA was enhanced by 
physiological levels of insulin (10-100pU.mH), although these same concentrations
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were unable to enhance responses to endogenous NA released as a result of 
periarterial nerve stimulation (Townsend et al., 1992). It seems probable that, if 
insulin does enhance responses to SNS activity, it is through a post-synaptic effect 
because the infusion of insulin at physiological levels into healthy subjects was without 
effect on plasma adrenaline (Adr) and NA concentrations even after 12 hours 
(Mitrakou et al., 1992). This does not exclude the possibility that hyperactivity of the 
SNS has a role to play in essential hypertension. Indeed evidence both for this and 
hyperinnervation of blood vessels (including resistance vessels) in the SHR has been 
forthcoming (for review see Head, 1989), which implies a positive role for the SNS in 
the development of hypertension. Any effect which insulin may have on this system, 
however small, could be important because of the chronic nature of the disease. The 
same can be said of insulin's other effects. The differences made may be so small in 
the short term that they are not readily measurable with current techniques.
It is also possible that insulin has central actions. Although it is not known 
whether the hormone can cross the blood brain barrier, even where the blood brain 
barrier is less selective around the circumventricular organs, it has been shown to have 
activity in the brain (Shian and Lin, 1991). These investigators found that injection of 
insulin into the anterior or lateral hypothalamic regions stimulated a dose dependent 
increase in glucose and insulin concentrations in the blood. However, the doses given 
to the rats appear to have been very high - roughly 1000-fold greater than the normal 
plasma content per millilitre. This may not be important since the injections into the 
ventromedial hypothalamus did not have the same effect.
It is well known that insulin can stimulate certain ion transporters in the plasma 
membrane. The two most important of these are the Na+/K+ ATPase which is 
translocated to the plasma membrane (Hundal et al., 1992; Omatsu-Kanbe and 
Kitasato, 1990) and the Na+/H+ antiporter (Vara and Rozengurt, 1985). The
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consequences o f this action are twofold. Firstly, the cells in which it occurs (the 
experiments were carried out using rat and frog skeletal muscle for the Na+/K+ 
ATPase) will become hyperpolarised, making them less immediately reactive. 
Secondly the stimulation of the Na+/H+ antiporter will raise intracellular pH, which 
tends to promote cell division. This is a property which insulin shares with epidermal 
growth factor (EGF) (Vara and Rozengurt, 1985).
These hypotheses do in fact correspond with what is found experimentally. 
Three groups have shown that Na+/K+ ATPase activity is increased in the SHR and 
essential hypertensive man compared with their controls. Touyz and associates (1992) 
showed this difference in human platelets and red blood cells, whereas Syme and 
colleagues (1990b) and Orlov and co-workers (1992) demonstrated it in SHR skeletal 
muscle and VSMC respectively. One report o f unchanged skeletal muscle Na+/K+ 
ratio in man (Landin et al., 1991) implies that the Na+/K+ ATPase is functioning 
normally in essential hypertension, but such findings are outnumbered by the 
previously quoted evidence.
Likewise the findings with the Na+/H+ antiport system have been revealing. 
The antiporter generates a greater H+ extrusion flux in SHR VSMC cultures than in 
WKY rat VSMC cultures (Davies et a l, 1991) and this was associated with an 
increased Vmax. These investigators also noted that the basal intracellular pH of SHR 
VSMC was significantly higher than that of corresponding cells from WKY rats. In 
contrast, another report also found an increased rate o f Na+/H+ exchange, but these 
authors came to the conclusion that this was due to an altered affinity of the carrier for 
intracellular H+ ions (Syme et al., 1990a). The promotion of Na+/H+ exchange and 
the observation o f raised intracellular pH in VSMC cultures from SHRs highlights 
another possible role o f insulin in causing hypertension, that of stimulation of cell 
division. This typically manifests itself as an increased medial thickness in the artery
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wall.
These are the two major changes, but not the only ones in essential 
hypertension. Both Ca*4- ATPase and Mg** ATPase show reduced activity in SHRs 
(Touyz et al., 1992). The reduction o f Ca4^  ATPase turnover in particular would lead 
to an increased intracellular free Ca4-1" concentration which would in turn enhance 
muscular contractility, if the results from platelets can be extrapolated to VSMC.
Folkow proposed in 1958 that a thickening of the media of hypertensive 
arteries and resistance vessels would decrease the lumen of these vessels due to 
encroachment of the extra muscle mass. This has been observed by many investigators 
and leads to the greater passive resistance of SHR vascular beds as compared with 
those from Wistar rats (Komer et al., 1991). It also accounts for the frequently 
observed increase in absolute response o f blood vessels to pressor substances while 
sensitivity remains the same (Mulvany, 1991).
There are two possible theories about the relationship between medial 
thickening and hypertension. The first is simply as an adaptive process to reduce 
vessel wall stress in response to increased pressure (Gibbons, 1991). The second 
suggestion is that vascular hypertrophy or hyperplasia is a cause of hypertension. The 
former suggestion gains support from Bund and his colleagues (1991) who 
demonstrated that reducing pressure in the femoral vascular bed of the SHR by tying a 
ligature around the iliac artery was sufficient to prevent the development of medial 
thickening. Between five and 12 weeks o f age the protected arteries in the SHRs were 
structurally indistinguishable from unprotected arteries in WKY rats. The latter 
hypothesis gains credence from the finding that media thickness is already increased in 
young SHR, even before they have raised blood pressure (Mulvany, 1990).
The oncogene product p21Hras, one of a family of similar guanine nucleotide
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binding proteins with low GTPase activity, has been shown to be linked with many 
growth promoting systems, for example signal transduction of nerve growth factor and 
EGF stimuli (Burgering et a l ,  1991). In the presence o f p21Hras insulin is able to 
stimulate the expression o f c-fos, c-jun, and p33 in various transformed cell lines. In 
fact, as an inducer o f c-fos expression and DNA synthesis insulin is as potent as 
insulin-like growth factor 1 (IGF-1) in 3T3-L1 adipocytes (Weiland et a l,  1991). (c- 
fos and c-jun are proto-oncogene products which are formed rapidly and transiently 
when, for example, growth hormone stimulates cell surface receptors. They bind to 
specific DNA sequences to activate gene transcription and cell growth or 
differentiation.) In addition to hyperinsulinaemia (as with plasma membrane ATPases, 
growth promoting mechanisms do not appear to be insulin resistant in the same way 
that glucose uptake is) other driving forces exist to enhance cell proliferation in 
response to insulin. Not only can high concentrations of insulin stimulate the IGF-1 
receptor, but so also can activated insulin receptors (Tartare et al., 1991). Since the 
insulin receptor is not the cause o f insulin resistance, this represents a second route by 
which insulin can stimulate cell proliferation.
Insulin-stimulated cell proliferation could be exacerbated by other properties of 
cells from hypertensive rats. Mesenteric artery myocytes from rats will grow in 
response to EGF provided either foetal calf serum (FCS) or insulin is also present. 
Myocytes from SHR need less insulin than cells from WKY rats in order to be 
competent to respond to EGF (Bukoski et al., 1991). The general trend towards more 
rapid division than normal cells has also been noted in aortic VSMC from SHR (Miller 
et a l, 7990). As the experiments o f Miller and colleagues suggest, the over- 
proliferative response seems to be a generalised feature of VSMC from SHR. 
Excessive responses have also been seen upon stimulation with angiotensin II (All) 
(Miller et a l ,  1990; Baudouin-Legros et a l,  1990), EGF, bFGF and three platelet-
27
derived growth factor variants (Saltis et al., 1993).
Medial thickening is not due only to muscle cell growth. Another very 
important factor is the laying down of more extracellular matrix, principally elastin and 
collagen (Keeley et al., 1991). It is this, rather than the increased VSMC bulk, which 
reduces vascular compliance and results in high systolic pressures. The half life of 
these proteins is very long (60-90 days for collagen, and longer than the lifetime of 
experimental animals for elastin) and this could account for the very lengthy therapy 
which is required before visible beneficial effects are seen in the structure of resistance 
vessels in man (Keeley et al., 1991). Although it is not known whether insulin is able 
to stimulate extracellular matrix deposition, this could be an important factor in the 
maintenance of the disease.
Insulin is also able to stimulate the production of the pressor substance 
endothelin 1 (ET-1) by endothelial cells (Oliver et al., 1991). However, thoughts that 
insulin might increase tubular resorption of sodium in the kidney, thereby inducing 
plasma volume expansion, appear to have been refuted by the discovery that insulin- 
stimulated sodium resorption is normal in type 2 diabetic patients (Skott et al., 1991).
A good case for insulin playing a role in the genesis of essential hypertension 
can therefore be made, but all may not be as seems. In a paper entitled "In defence of 
insulin - a critique o f syndrome X", Jarrett (1992) set out to question many of the 
foundations upon which the pathological role of insulin resistance is based. Syndrome 
X was proposed by Reaven in his 1988 Banting lecture. It consists of an association 
of raised very low density lipoprotein (VLDL), lowered high density lipoprotein 
(HDL), glucose intolerance, insulin resistance and hypertension. Jarrett points out that 
a number of studies which found no, or only poor, correlation of indices of insulin 
resistance with blood pressure have been reported. Obesity, if not properly taken into
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account, is likely to be the most significant confounding factor in studies o f this 
relationship, and the point that evidence is difficult to compare due to differing and 
unproved methodologies is a good one. Nevertheless, at least as much evidence exists 
to support the claims that Reaven and many others make as can be found to challenge 
them.
Treatment of hypertension.
Since the 1940s great advances have been made in the drug treatment of 
hypertension. The battery o f chemical weapons now available to the medical 
profession is both varied and sophisticated. Indeed, there are eight or nine different 
classes o f drug which have been developed (although some are not now used because 
of their side effects) with several others in the laboratory undergoing evaluation. As a 
result, the control of blood pressure has, in nearly all cases, become very good, and the 
number o f cardiovascular incidents which are known to stem from high blood 
pressure, such as strokes, have been reduced in direct proportion with the quality of 
blood pressure control. However, the improvement in antihypertensive therapy has 
had little effect on the incidence of heart failure and myocardial infarction (Sever, 
1986). Indeed, data from the Australian Therapeutic Trial in Mild Hypertension 
(1980) suggested that at each level of (average diastolic) blood pressure, the incidence 
of stroke, myocardial infarction and related conditions was higher in the drug-treated 
group of patients, implying that the drugs used were actually an added risk factor. 
The reason for this is not known, but one o f the most widely proposed theories is that 
while reducing the risk factors o f high blood pressure they also worsen other risk 
factors. Chief among these are glucose and lipid metabolism (Shionoiri et al., 1990; 
Lithell et al., 1990). For example, both metoprolol and atenolol have been reported to
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decrease the insulin sensitivity index, by 27% and 23% respectively, in essential 
hypertensive patients, as well as increasing VLDL cholesterol and triglyceride 
concentrations, increasing low density lipoprotein (LDL) triglycerides, and reducing 
HDL cholesterol levels (Lithell et al., 1990). Similarly hydrochlorothiazide reduced 
the insulin sensitivity index by 16% and raised serum cholesterol and triglyceride 
levels, especially LDL cholesterol in essential hypertensives (Pollare et al., 1989).
This may not be the case for all antihypertensive drugs. The calcium channel 
blocker diltiazem was found not to worsen the insulin sensitivity index and had no 
effect on triglyceride and cholesterol levels (Lithell et al., 1990). In contrast, the 
angiotensin converting enzyme (ACE) inhibitor captopril was shown to improve the 
insulin sensitivity index by 18% without affecting lipoprotein concentrations (Pollare et 
al., 1989). Insulin sensitivity has also been determined by Torlone and co-workers 
(1991) who showed that both hepatic and extrahepatic insulin sensitivity in type 2 
diabetics with hypertension were greater after captopril than placebo. Gans and 
colleagues (1991a) were likewise able to determine a greater effect o f an insulin 
infusion after treatment o f normal volunteers with enalapril than after saline treatment. 
The results have not been entirely consistent, though. In two studies of the actions of 
ACE inhibitors on glucose tolerance and insulin sensitivity, Shionoiri and colleagues 
were unable to demonstrate an action, on these parameters, of captopril (Shionoiri et 
al., 1987) or lisinopril (Shionoiri et al., 1990) in hypertensive patients. Consequently 
the literature does not yet direct one to draw any firm conclusions concerning the 
efficacy o f ACE inhibitors in improving insulin sensitivity, but it does seem that |3 
blockers and diuretics may have adverse effects upon insulin sensitivity. In this respect 
both ACE inhibitors and Ca++ channel blockers may have an edge over more 
conventional drugs in the treatment of hypertension, and further investigation of their 
properties in affecting metabolic functions is clearly warranted.
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The renin angiotensin aldosterone system.
Although the renin angiotensin aldosterone system (RAAS) will not feature 
greatly in the discussion o f the results presented hereafter, an overview of it will now 
be set out in order to place the main actions o f the ACE inhibitors used in the project 
in their proper context. (For review see Opie, 1992)
The RAAS is a feedback system which has evolved to regulate the body’s 
electrolyte balance and blood pressure. Its function is therefore intricately involved 
with the kidney.
Its activity is increased when renin is released from the juxtaglomerular cells o f 
the nephron in the kidney. This occurs in response to one or more of three main 
stimuli, which are impaired renal blood flow, reduced plasma Na+ content, or (3 
adrenergic stimulation. Renin proteolytically cleaves the plasma borne factor 
angiotensinogen to release angiotensin I (Al), a decapeptide, which is itself acted upon 
by ACE to form the octapeptide angiotensin II (All). A ll is the active constituent of 
the system, and has three main actions. It causes vasoconstriction by increasing C a ^  
entry into VSMC, it enhances sympathetic activity which also leads to 
vasoconstriction, and it causes the adrenal cortex to release the Na+ retaining hormone 
aldosterone. A il is then broken down to angiotensin III which has no vasoconstrictor 
activity, but retains some aldosterone releasing activity (Opie, 1992) (figure I 3).
ACE inhibitors, therefore, have three potential angles of attack on hypertension 
in the short term, provided the RAAS plays a reasonably important role in the 
maintenance of high blood pressure. By inhibiting the formation of A ll they remove 
elements o f vasoconstriction, adrenergic facilitation, and plasma expansion through the 
Na+ retaining properties o f aldosterone. In the long term, by contrast, A ll may act as 
a growth factor and thereby promote vascular wall hyperplasia and hypertrophy
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Figure 13. Schematic diagram of the generation of angiotensin II and the breakdown of bradykinin. 
ACE - angiotensin converting enzyme.
(Baudouin-Legros et al., 1990; Dzau and Gibbons, 1991).
The measured plasma concentration of renin in most essential hypertensives is 
normal (Opie, 1992) as it is in the SHR (Fujito et al., 1992). (Plasma renin 
concentration is used as a marker of the degree of RAAS activation). This would 
suggest that renin release is not a cause of hypertension and that ACE inhibitors would 
not have a great hypotensive effect. This is not the case, however. It has become 
accepted that there is a tissue RAAS which is important both to regional blood flow 
control and the development of essential hypertension. The expression of genes for 
renin, angiotensinogen, and ACE have all been demonstrated in brain, kidney, and the 
vasculature (for review see Lee et a l , 1992), and data presented in the literature 
strongly imply the presence o f a fully competent and functional RAAS in the vascular 
walls of the rat (Egleme et al., 1990; Mizuno et al., 1988). Actions on the tissue 
RAAS must, therefore, also be taken into account when studying the site of action of 
ACE inhibitors.
Besides these conventional actions of ACE inhibitors, however, are two other 
activities of drugs such as captopril which may have an important bearing on their 
effect in hypertension. The first o f these is dependent on the fact that ACE is also 
known as kininase II, the enzyme responsible for the breakdown of bradykinin (Bk) 
(Sofifer et a l,  1974). ACE inhibitors, therefore, prevent the catabolism of Bk and 
thereby increase its concentration in the blood, and, due probably to a local Bk 
generating system, in the vessel wall also (Wiemar et a l , 1991). Bk is a direct 
vasodilator, and a substance which induces the release of EDRF and vasorelaxant 
prostanoids from the endothelium (Wiemar et a l ,  1991; Hoffmann et a l, 1990). 
Additionally, it appears that it could be at least partially responsible for the regression 
of the cardiac hypertrophy commonly seen with long term ACE inhibitor therapy (Linz 
and Scholkens, 1992), and the similar vascular hypertrophy (Farhy et a l ,  1992) since
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antagonists o f Bk have been used to prevent ACE inhibitor-induced regression.
The second property o f ACE inhibitors is the ability, at least, it seems, in some 
circumstances, to improve glucose tolerance and insulin resistance, as has been 
mentioned already. The mechanism by which they have this effect is completely 
unknown, the research to date having focused on the simple observation that these 
drugs do have this property. It is not clear how the RAAS might interact with insulin- 
stimulated glucose uptake. The only major connection between the two systems is 
through the control o f electrolytes, since both insulin (Omatsu-Kanbe and Kitasato, 
1990; Hundal et al., 1992) and aldosterone (Bia and De Fronzo, 1981) are able to 
stimulate Na+/K+ ATPase and play an important part in Na+/K+ regulation. Plasma K+ 
concentration in hypertension is lower than in normotension, and this may be due to 
the high concentrations o f insulin and aldosterone present in the plasma (Kim et al., 
1991). A self-compounding aspect of low plasma K+ concentrations is that this 
stimulates renin release, and the subsequent rise in A ll stimulates further K+ excretion 
via aldosterone release (Ferrannini et al., 1992). It could be, then, that the excessive 
amounts of these two hormones combine to stimulate cell growth and division through 
the stimulation o f Na+/K+ ATPase and the consequent activation of the Na+/H+ 
exchanger which raises intracellular pH. Allied to the fact that VSMCs from SHRs are 
generally over-responsive to mitogenic stimuli anyway (Miller et al., 1990, Baudouin- 
Legros et al., 1990) such circumstances provide a powerful reason for believing that 
vascular hypertrophy and hyperplasia is a cause of essential hypertension, and not an 
adaptation to it. The action of ACE inhibitors, therefore, would reduce one of these 
stimuli. Indeed, one of the most vaunted properties of ACE inhibitors is the ability to 
reduce both cardiac and vascular hypertrophy (Clozel et al., 1991, 1992; Frelson and 
Giudicelli, 1983).
This theory might explain why ACE inhibitors have such a marked effect on
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vascular growth, but it does not explain why they appear to have an effect on glucose 
tolerance and insulin resistance. Glucose tolerance may be reduced in essential 
hypertension as a result o f the lower plasma K+ concentration, which provides a 
reduced stimulus for insulin secretion (Ferrannini et al., 1992), but this does not 





The aims of this project were to cover two main areas in hypertension 
research. The first of these was to investigate a model of insulin resistance and use it 
to determine whether the properties claimed for ACE inhibitors in humans 
(amelioration of insulin resistance) could be achieved in animal models both in vivo 
and in vitro. The second thread of the investigation was to carry out some work to 
elucidate any differences in K+ metabolism in vivo by using plasma K+ concentration 
as an indicator of K+ status, and how this might relate to glucose metabolism.
From these approaches it was hoped that some conclusions about the cause of 
insulin resistance might be drawn, and further evidence for or against ACE inhibitors 






All animals were male Wistar or Japanese Okamoto spontaneously 
hypertensive rats bred in the colony held at the University of Bath. They were housed 
in the University of Bath animal unit, and subjected to a twelve hour light: dark cycle, 
with the lights coming on at 6am. They drank tap water and ate SDS animal chow 
(Special Diet Services, Manea, Cambridgeshire), both supplied ad libitum.
Rats were fasted overnight (16-20 hours) prior to an experiment, and weighed 
250-350g before fasting if they were to be used for glucose tolerance experiments, and 
200-250g for isolated diaphragm experiments.
Anaesthesia, cannulations, injections and samples.
Rats were anaesthetised by intraperitoneal injection of anaesthetic. When 
surgical anaesthesia had been achieved the trachea was cannulated to allow artificial 
ventilation at 48 strokes.min*1 with a stroke volume of 0.75ml. 100g‘l body weight if 
necessary. The two internal common carotid arteries were then cannulated with 
polythene cannulae (Portex cannula, external diameter 1.02 mm) as was a femoral vein 
(Portex cannula, external diameter 0.63 mm). Cannulae were tied in place with cotton 
ties.
One carotid cannula was connected, through a three way tap, to a blood 
pressure transducer (Bell and Howell, type 4-422-0001) the signal of which was 
processed by a pre-amplifier (Lectromed, model 3576) and recorded on a chart 
recorder (Lectromed, model MX2). Phasic blood pressure was recorded. The second 
carotid cannula was also attached to a three way tap, and this was used to remove
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0.2ml blood samples for analysis o f blood glucose, potassium, and insulin 
concentrations, as appropriate. It was also used to replace the volume of blood 
removed with an equal volume of 0.9% (w/v) saline solution. On some occasions it 
was only possible to cannulate one carotid artery. When this happened the single 
cannula was be used to record blood pressure before and after glucose tolerance tests, 
but during the tests it was used for sample withdrawal and volume replacement.
The femoral vein cannula was used for administration of drugs and glucose. 
Each dose was washed through the cannula with 0 .1ml 0.9% saline solution which was 
roughly equal to the dead space of the cannula.
The animals were kept warm throughout the experiment on a small animal 
heating table (Scientific Research Instruments), their rectal temperature being 
maintained between 35.5 and 38.5°C, with an ideal temperature of 37°C.
Before all protocols with anaesthetised animals were started, but after they had 
been cannulated, the animals received 600units.Kg_1 heparin intravenously. Cannulae 
were also initially filled with heparin at a concentration of 1000 units.ml-1.
Comparison of plasma elucose concentration in freshly killed Wistar rats and 
SHRs.
A group o f six Wistar rats (300-350g) was compared with a similar group of 
SHRs. Each animal was sacrificed by cervical dislocation, and immediately 
decapitated: Approximately 1.5ml of thoracic blood Was collected from each rat.
Each of the six samples for each group was then treated as detailed later, and analysed 
for glucose concentration.
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Development of the intravenous glucose tolerance test model.
Assessment of anaesthetic suitability.
Two anaesthetics were initially tested in Wistar rats. These were urethane 
(MOOmg.Kg-1) and hypnorm cocktail (0.4ml. 100g_1). Both were injected 
intraperitoneally. After induction of anaesthesia and cannulation of blood vessels and 
trachea, a blood sample was taken at t=0 and every 15 minutes after that, up to and 
including a two hour sample. The samples were treated as detailed later, and analysed 
for glucose concentration. Figure Ml shows the result of this experiment. As can 
clearly be seen, the control of plasma glucose concentration varied considerably less in 
the hypnorm cocktail-injected rats than in those which had been injected with urethane 
to induce anaesthesia. As a result of this study, hypnorm cocktail was chosen as the 
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Figure M l.  Effect of anaesthetic on basal plasma glucose concentration m Wistar rats. Symbols 
are:. O - urethane anaesthesia (n=3 except where indicated), or #  - hypnorm cocktail (n=3. except 
where indicated) Urethane ( KOOmg.Kg'1) or hypnorm cocktail (4 0ml Kg'1) were injected 
intraperitoneally Points represent mean ±sem, here and in all following legends
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A comparison was then made of the quality of the control of plasma glucose 
concentration in Wistar rats and SHRs. Figure M2 shows that SHRs had a 
significantly higher basal plasma glucose concentration than Wistar rats, and that this 
difference was maintained at all time points except t= 105 minutes. The narrowing of 
the gap over the two hours appeared to be due to an increase in plasma glucose 
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Figure M2. Effect of rat strain on basal plasma glucose concentration m hypnorm cocktail- 
anaesthetised rats. Symbols are O - Wistar rat (n=5. except where indicated), or #  - SHR (n=5, 
except where indicated). ** P<0.01. compared with the concentration m Wistar rats, by ANOVAR 
and post hoc Studentised range test
However, particularly in SHRs, it proved very difficult to maintain surgical 
anaesthesia without risking overdosing the animals. Therefore when a third 
anaesthetic, inactin, became available, it, too, was investigated. Hypnorm cocktail was 
compared with inactin in a similar protocol to the comparison with urethane. Inactin 
was injected intraperitoneally at a dose o f  150mg.Kg~'. As well as proving much more
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reliable in inducing anaesthesia, it had the additional advantage that it did not need 
topping up in the majority o f  animals, so depth o f  anaesthesia, judged by the paw 
withdrawal and blink reflexes, was much more constant than with hypnorm cocktail. 
Idie result o f  this comparison is shown in figure M3. This figure demonstrates that 
there is 110 difference in the quality o f  control o f  basal plasma glucose concentration 
between rats anaesthetised with hypnorm cocktail or inactin. In hypnorm cocktail- 
anaesthetised rats the basal plasma glucose concentration was approximately ImM 
higher than in inactin-anaesthetised rats. The possible reasons for this difference wall 
be discussed later. Inactin was therefore chosen to continue the studies, and some 
experiments were repeated using the new anaesthetic. The results represented by 
figure M4, and all o f  the in vivo results in the results section (except the assessment o f  
epicaptopril activity and the assessment o f  the ability o f  losaitan to inhibit AI pressor 
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Figure M3. Basal plasma glucose concentration in SHRs anaesthetised with different anaesthetic 
agents Symbols are: O - hypnorm cocktail anaesthesia (iw3, except where indicated), or #  -




Intravenous glucose tolerance tests (IVGTTs) were performed in the following 
manner. At t=-2 minutes a basal blood sample was taken, followed at t=0 by 
intravenous (iv) administration o f 250mg.Kg_1 (1.39mmol.Kg-1) glucose in solution. 
Then, at t=2, 5, 10, 15, and 30 minutes further blood samples were taken.
Where two IVGTTs were carried out in the same animal, either 30 or 60 
minutes was allowed between the two tests for the animals to re-establish baseline 
glucose and insulin concentrations. This time period was constant within an 
experiment. Drugs were administered 27-30 minutes before the second IVGTT, 
except in the case of lisinopril which was administered 57 minutes before the second 
test.
Assessment of the effect of time between two IVGTTs on the second
IVGTT.
In this study two IVGTTs were carried out in each animal, the time between 
the two tests being either 30 minutes or one hour. No other treatment was given to 
either group of SHRs used for this investigation.
The results of this experiment, shown in figure M4, demonstrate that when the 
second IVGTT was performed one hour after the end of the first, the clearance of the 
glucose load was no different from that in animals in which only half an hour had been 
allowed between the two IVGTTs. This test was carried out to ensure that studies 
which had different times between the two IVGTTs could be considered similar, and 
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Figure IVI4. The effect of time between two IVGTTs on the second IVGTT in inactin anaesthetised 
SHRs. Symbols are: O - half an hour (n=5), or •  - one hour between IVGTTs.
Chronic treatm ent of SHRs with captopril.
The investigations were also extended to cover a possible chronic action o f  
captopril. In this case the drug was injected subcutaneously twice a day (at 9ani and 
4pm) in two equal doses so that each animal received 230umol.Kg-i per day for two 
weeks. After this period the animals were subjected to an IVGTT as for acute 
experiments. Animals were tested in pairs o f  one each o f  the control and treated 
groups. On the experimental day only animals to be used in the afternoon received the 
morning injection. The captopril was dissolved in saline and a similar volume o f  saline 
was injected into the control animals as vehicle.
Assessment of the efficacy of Lisinopril and losartan.
For the assessment o f  angiotensin II (All) antagonism by losartan SFIRs were 
anaesthetised with hypnorm cocktail and cannulated as previously described, except 
that only one carotid cannula was used. Blood pressure was recorded throughout the
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experiment. The effect o f a bolus of saline (0.5ml.Kg_1, iv) on blood pressure was 
assessed, and any increase in blood pressure that this caused was subtracted from 
subsequent responses to angiotensin II. A dose:response curve of increases in blood 
pressure in response to bolus doses of All (iv) was then constructed, after which a 
dose of losartan was injected intravenously. Thirty minutes was allowed for the drug 
to take effect, after which a second dose:response curve was performed.
The assessment of lisinopril activity was similar, except that inactin was used 
to anaesthetise the rats.
Treatment and analysis of samples.
Blood samples were immediately transferred to 0.4ml Sarstedt tubes and 
centrifuged (Beckman Microfiige II) for one and a half minutes to remove 
erythrocytes and white blood cells. The plasma was collected and stored on ice, either 
until it was analysed after the experiment, or until the end of the experiment when it 
was frozen to -20°C.
Samples were routinely analysed for glucose concentration, and on occasions 
also for K+ and insulin concentrations.
Glucose concentration was determined using a glucose oxidase-based 
colourimetic assay (GOD-Perid kit, Boehringer-Mannheim). This was carried out 
according to the supplied instructions, with three alterations. The enzyme solution 
was made up at lOmg.mH, of which 2ml per assay was used, and the volume of 
plasma sample used for each replicate was 5pi. Briefly, 5pi of sample was pipetted 
into a test tube and 2ml o f enzyme solution added to it. After whirlimixing, it was 
incubated at room temperature for 30 minutes while it developed a green colour, at 
which time the intensity of the colour was measured in a spectrophotometer (Pye-
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Unicam, model 8610) at 436nm. Assays were performed in duplicate. A standard 
curve was constructed for each set of assays using known glucose concentrations. 
The standard curve assays were done in triplicate.
K+ concentration was measured using flame photometry (Coming 405 flame 
photometer). 1.98ml o f Coming 405 diluent solution was added to 20pl o f plasma 
sample. After whirlimixing, the sample was read straight away. The flame photometer 
was re-calibrated after every fourth sample reading.
Insulin concentrations were measured by radioimmunoassay. This was kindly 
done by staff at Zeneca Pharmaceuticals PLC (Alderley Park, Cheshire), and was 
based on a method by Albano and colleagues (1972).
The assay depends on competition for a limited number of binding sites on a 
fixed amount of antibody (Ab). Radiolabelled insulin competes with plasma insulin for 
the Ab binding sites. After equilibrium is reached, the free and bound radioactive 
insulin are separated by charcoal absorption.
The quantities indicated in columns 1 to 6 of table M l were added to LP3 tubes, 
mixed, and incubated at 4°C for five hours. Then the quantities of buffer solution or 
charcoal solution in columns 7 and 8 were added to the contents of the tubes, mixed 
in, and left to incubate at 4°C overnight. The tubes were then centrifuged at 2500 rpm 
(Sorvall RC-3B centrifuge) for 30 minutes at 4°C, and 500gl of the supernatant 
transferred to LP3 tubes for counting of the radioactivity (LKB-WALLAC universal
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Table M l. This table represents the constituents, and quantities of those constituents, which were 
used in the insulin radioimmunoassay. Refer to text (page 47) for order and timing of mixing.
All volumes are in pi. Abbreviations are: TC - total count of radiolabelled insulin; CB - charcoal 
blank, CTP - charcoal-treated plasma; AIS - anti-insulin serum; A - standard buffer A solution;; B 
- standard buffer B solution; ,25I - radioactive insulin; Std - lyophylised rat insulin standard; ch a r- 
activated charcoal solution.
1 2 3 4 5 6 7 8
B Std CTP A AIS 125 j A Char
TC 100 700
CB 50 50 200 100 400
Zero 50 50 200 100 400
Std 50 50 200 100 400
Sample 50 200 100 400
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gamma counter (window 035-102, count time 60 seconds)). A standard curve was 
drawn, from which sample concentrations were interpolated.
Charcoal treated plasma was prepared as follows: the plasma samples were 
defrosted, and lOmg.lOOpH charcoal was added, and mixed at room temperature for 
30 minutes. Next the samples were centrifuged at 18,000 rpm for 20 minutes. The 
supernatant was then filtered and used in the radioimmunoassay.
M easurement of glucose uptake by rat hemidiaphragm.
This method is an adaptation of the method used by Kirby and Turner (1975).
Rats were killed by stunning and then cervical dislocation. Diaphragms were rapidly 
excised, given three washes in ice cold, glucose-free Krebs solution, and rested in ice 
cold, glucose-free Krebs solution for ten minutes. The dissection and washing took 
about 90 seconds. They were then divided into halves that were trimmed, blotted, and 
weighed, and placed into the incubation flasks. The flasks contained 3ml o f previously 
oxygenated incubation mixture which was glucose-containing Krebs solution with the 
appropriate concentrations o f human insulin and drug. A constant stream of water- 
saturated 95%02/5%C02 was passed through each flask to ensure adequate oxygen 
supply. In experiments where a concentration:effect curve for insulin was constructed, 
each hemidiaphragm was randomly assigned to one of the concentrations o f insulin 
being tested. When the effect o f captopril on insulin-stimulated glucose uptake was 
being assessed one of each pair of hemidiaphragms was used as control and received 
vehicle while the other received drug. These were also randomly assigned to drug or 
control treatment.
The flasks were placed in a heated (37°C), shaking (150 strokes.min-1) water 
bath for two hours. 50pl samples were taken of the initial incubation medium, and of
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the flask incubation medium at t= 10 and 20 minutes, and every 20 minutes thereafter 
up to and including a t= 120 minutes sample. Samples were kept on ice until analysed, 
or until frozen to -20°C to be analysed on another day. At the end of the experiment 
the remaining volume o f incubation medium was measured and an estimation of the 
rate of evaporation due to the continuous gassing was made.
The glucose concentrations were determined, and estimates of cumulative 
glucose uptake by each hemidiaphragm were made by subtracting the measured 
concentration from the initial concentration, taking into account sample volume loss 
and the concentrating effect o f evaporation. The mass o f glucose taken up by each 
diaphragm was expressed as pmol uptake.g' 1 tissue wet weight.
Assessment of aldosterone and canrenoate potassium effects on plasma glucose 
and potassium concentrations.
SHRs or Wistar rats weighing 250-300g were anaesthetised and prepared, as 
previously described, after being fasted overnight. After approximately 30 minutes, 
during which the animals stabilised, the experiment was started.
In the aldosterone assessments, three basal blood samples were taken, at t=0, 
10, and 20 minutes. Immediately after the 20 minute sample a dose of aldosterone 
(1.39nmol.Kg"1), which would produce an incremental increase in plasma aldosterone 
concentration of approximately 15- to 70-fold, was administered iv. Further samples 
were taken at 10 minute intervals until the termination of the experiment at t= 180 
minutes. Samples were treated, and assayed for glucose and K+content as described 
previously.
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The assessment o f canrenoate K+ action was carried out similarly. At t=0 and 
20 minutes basal blood samples were taken, immediately after which a dose of 
7.5mol.Kg_1 canrenoate K+ was given iv. Samples were taken, for estimation of 
plasma glucose and potassium concentration, every 10 minutes until t=60 minutes, 
after which they were taken every 20 minutes until t= 180 minutes when the 
experiment was ended.
Materials and solutions.
All salts for Krebs' solution were supplied by BDH Chemicals Ltd., Poole, 
Dorset, as was the D-glucose used throughout the studies. L-cysteine, aldosterone 
and canrenoate K+ were supplied by Sigma Chemicals Ltd., Poole, Dorset. Human 
insulin was "Actrapid" (lOOIU.ml-1) from Farillon Ltd., Romford, Essex.
The ACE inhibitors were all generous gifts of industrial companies. Both 
captopril and epicaptopril were supplied by the Squibb Institute for Medical Research, 
Piincetown, New Jersey, enalaprilat was given by Merck Sharpe and Dohm Ltd., 
Rahway, New Jersey, and lisinopril was from Zeneca Pharmaceuticals, Alderley Park, 
Cheshire.
The glucose oxidase kit (GOD-perid method) was obtained from Boehringer- 
Mannheim Diagnostica, Lewes, East Sussex.
Urethane was obtained from Sigma Chemicals Ltd. Inactin was purchased 
from from Byk-Gulden, Konstanz, Germany. Hypnorm was supplied by Janssen 
Pharmaceuticals Ltd., Grove, Oxford, and Hypnovel by Roche Products Ltd., Welwyn 
Garden City, Herts.
Heparin was supplied by Sigma Chemicals Ltd, as were human angiotensins I
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and II.
The saline to make up the captopril solution during the chronic captopril 
treatment was from Steripak.
Urethane (crystalline form) was made up as a MOOmg.mH solution in distilled 
water, and kept at 0-4°C for two weeks. "Hypnorm cocktail" was made up by mixing 
one volume of hypnorm, one volume of hypnovel, and two volumes of sterile water. 
The final concentrations o f the active constituents were 78.8jig.ml'1 fentanyl citrate, 
2.5mg.ini' 1 fluanisone, and 1.25mg.ini'1 midazolam. It was stored at room 
temperature in the dark for up to one month. Inactin, supplied as a powder, was 
dissolved in distilled water to a final concentration of 50mg.mH. It was divided into 
aliquots and these were frozen (-20°C) until used. Heparin was dissolved in 0.9% 
saline solution and made up to a final concentration of lOOOU.ml' 1 before being 
aliquotted and kept at 0-4°C. The saline solution (0.9% w/v) was made up with 
distilled water.
D-glucose solution was made up to 250mg.mH (1.39M) in distilled water. It 
was kept at 0-4°C between experiments, for not longer than two weeks.
Captopril (2.3x10_6mol.ml"1), epicaptopril (2 .3xl0 '6mol.ml'1), enalaprilat 
(l^x lO ^m ol.m l'1), lisinopril (2 .75xl0 '7mol.ml'1), losartan (2.17xl0‘5mol.ml_1), and 
L-cysteine (2.3xl0 '6mol.ml*1) were all dissolved in 0.9% saline solution. Likewise, 
solutions of aldosterone (1.39xl0 '9mol.ml"1) and canrenoate K+ (7 .5xl0 '5mol.ml'1) 
were made up in saline. In the study of the effects of chronically administered 
captopril, the drug was dissolved in sterile saline to a concentration of 1.15x1 O'4 
mol.ml-1. The solution was freshly made up for each injection time.
Krebs' solution contained the following compounds in the designated 
concentrations: NaCl 118.4mM, KC1 4.7mM, CaCl2 2.5mM, NaHC03 25mM, M gS04
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1.2mM, KH2P 0 4 1.2mM, and D-glucose 15mM. The insulin solution used to 
stimulate glucose uptake by hemidiaphragms was diluted with this Krebs' solution to 
the required concentrations, which were lOpU.ml'1, lOOpU.ml'1, ImU.ml'1, 
lOmU.ml'1, or lOOmU.ml"1.
Coming 405 diluent was made up by diluting a volume of the concentrated 
diluent 1000-fold with distilled water.
Statistics.
Graphs show mean values ± standard error of the mean (sem) throughout 
(except figure R 2). The data quoted in the text are also mean values ±sem.
The significance o f differences in blood pressure were tested using Student's t- 
test for unpaired data. The comparison of glucose tolerance curves was made with 
two way analysis of variance (ANOVAR) with replications in order to determine 
whether a difference existed between glucose extinction curves. Comparisons were 
made between the groups either before or after treatment with saline or drug, or 
between the two IVGTTs done in the same group before and after treatment. 
Similarly, comparisons o f insulin-stimulated glucose uptake and the effect of captopril 
on this parameter were tested using the same test, as were comparisons of the effect of 
aldosterone and canrenoate potassium on plasma glucose and potassium 
concentrations. Where a significant difference was indicated by the value of F in the 
ANOVAR, a post hoc studentised range test was carried out to determine where the 
significant difference lay. When the groups being tested were of equal size, the post 
hoc studentised range test was undertaken using the Tukey method, whereas for 
groups of unequal size the Tukey/Kramer method was used (Hinkle et al., 1988). 





Blood pressure in Wistar rats and SHRs.
Figure R 1 shows the mean systolic, diastolic, and pulse pressures recorded 
from the anaesthetised rats used in the comparison of intravenous glucose tolerance 
and insulin action in Wistar rats and SHRs (see below). As can be seen, there was a 
statistically significant difference between the two strains with respect to each 
parameter. These values were typical of the pressures recorded during the studies 
detailed in this thesis.
Glucose oxidase-based glucose assay.
The glucose oxidase-based assay used for measuring plasma glucose 
concentrations was highly reliable and reproducible. A sample of six standard curve 
assays, each performed in triplicate, had a positive gradient of 0.06882 ±0.00529 
absorbance units per millimolar increase in concentration (mean ±95% confidence 
intervals). These data are shown in figure R 2.
Plasma glucose concentration in freshly killed rats.
Plasma glucose concentration in freshly killed Wistar rats and SHRs rats did 
not differ significantly. The values were 8.0 ±0. ImM (mean ±sem, n=6) for Wistar 
rats and 8.6 ±0.3mM (n=6) for SHRs. These values are significantly higher than for 






















Measured pressure pa ram ete r
Figure R 1. Systolic, diastolic, and pulse pressures recorded in inactin-anaesthetised Wistar rats and 
SHRs. The data are from the rats used in the comparison of intravenous glucose tolerance and insulin 
action in Wistar rats and SHRs (figure R 3). Wistar rats (n=8 ) are represented by open bars and 




>3 1 . 0 0 0
E
g  0 .7 5 0
0 .5 0 0o
<DO
C
oJD 0 .2 5 0
o
CO
g  0 .0 0 0
>.00 10 .00  15.0
Concen t ra t ion  of  s tandard  (mM)
Figure R 2. Standard curve for glucose oxidase-based glucose assay Graph shows mean absorbance 
±95% confidence intervals and mean gradient (see text). The data represent six experiments each 
performed in triplicate.
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Comparison of intravenous glucose tolerance and insulin action in Wistar rats 
and SHRs.
Plasma glucose concentration was significantly higher in SHRs than Wistar 
rats at t=0 (3.4±0.1 (n=8) vs. 4.7±0.4mM (n=6), P<0.01) and remained so except at 
t=30 minutes. Moreover, the increase in concentration upon injection of glucose was 
greater in SHRs than in Wistar rats (7.4±0.7 vs. 5.5±0.2mM, P<0.01) at t=2 minutes 
(figure R 3, A). However, the area under the curve above initial concentration was 
not significantly different in SHRs compared with Wistar rats (81.4±7.9 vs. 80.1 
±10. ImM.min respectively), and at the end of the IVGTT the concentration of plasma 
glucose was still significantly higher than basal values in Wistar rats whereas it had 
returned to normal in SHRs.
The insulin response during the IVGTT (figure R 3, B) was significantly 
greater (P<0.01) in the SHR group than in the Wistar rat group, although the rise in 
plasma insulin concentration at t=2 minutes was not significantly larger in SHRs than 
in Wistar rats (5.74 ±0.76 (n=6) vs. 4.51 ±0.24 (n=4), respectively).
The 10 minute infusion of insulin (3.6mU.Kg-f min-1) to which the animals 
were subjected caused a significant drop in the plasma glucose concentration of both 
strains of rat (figure R 4). Interestingly, the response of SHRs appeared more marked 
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Figure R 3. Comparison of intravenous glucose tolerance in inactin-anaesthetised Wistar rats and 
SHRs (A), and the insulin response during IVGTT (B) I.39mmol.Kg'' glucose solution was 
administered intravenously at t=0. Symbols are: O - Wistar rats (n=8 ), or •  - SHRs (n-"6 )














Figure R 4. Effect of intravenous insulin infusion (3.6mU.Kg'! nun'1) on plasma glucose 
concentration in inactin-anaesthetised Wistar rats and SHRs. Symbols are O - Wistar rats (n=7). or 
)- SHRs (n=6 ). Bar indicates duration of infusion. * P<0.05, **P<0.01 compared with t=55 minutes 
in the same strain.
The  effect of cantopriL lisinopril,  a n d  ena lap r i l a t  on blood  p re ssu re  and  glucose 
tolerance in the SHR.
Captopril (2.3f.imol.Kg‘1, iv) failed to cause a reduction in diastolic blood 
pressure, either compared with initial values in the test group (where it fell front 84 
±10 to 80 ±9mmHg. n=6) or compared with control animals (the fall in pressure after 
saline treatment was 16 ±5mmHg whereas it was 4 -2m m Hg after captopril 
treatment).
Enalaprilat (1.3f.unol.Kg'1, iv) caused a significantly greater reduction in 
systolic blood pressure than saline, falling by 21 ±5mmHg to 1 11 ~19mmHg (n=^6) in 
controls compared with a decrease o f  41 ±7mmHg to 97 -: |5m m H g (n=6) in treated
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animals. The reduction in diastolic blood pressure was not statistically significantly 
greater in enalaprilat-treated rats (21 ±4mmHg in controls vs. 37 ±7mmHg in 
enalaprilat-treated animals).
Lisinopril (275nmol.Kg_1, iv) had no statistically significant effect on blood 
pressure parameters. In control animals diastolic blood pressure fell by 11 ±7mmHg 
to 58 ±9mmHg (n=6) after saline treatment. The reduction in this measurement in 
hsinopril-treated rats was by 22 ±13mmHg to 53 ±15mmHg (n=5). In spite of this, 
lisinopril at this dose had been previously shown to cause approximately a 100-fold 
shift to the right of the pressor dose:response curve in response to intravenously 
administered angiotensin I (figure R5).
Of the three ACE inhibitors, only captopril showed any effect on glucose 
tolerance (figures R 6 - R 8). Its action was to worsen glucose tolerance significantly 
(P<0.05) compared with the controls in which glucose tolerance did not change 
(figure R 6). The difference was demonstrated by analysis of variance, but post hoc 
Studentised range test revealed that no single pair of points differed significantly from 
each other.
The effect of chronic captopril treatment on glucose tolerance.
In the regime chosen for this experiment, captopril (230pmol.Kg*l.d ay 1 for two 
weeks) reduced both systolic (from 176±7mmHg in controls (n=4) to 159±9mmHg in 
treated animals (n=7)) and diastolic (from 148±10 mmHg in the control group to 114 
±8mmHg in the test group) blood pressures, although only the difference in diastolic 
blood pressures was statistically significant (P<0.01). The two weeks of treatment 
with captopril did not affect glucose tolerance (figure R 9) with respect to time course 
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Figure R 5. Effect of lisinopril (TySnmol.Kg"1, iv) on pressor responses of diastolic blood pressure to 
angiotensin 1 (iv) in inactin-anaesthetised SHRs. Symbols are: O - control dose:response curve, #  - 






















Figure R 6 . Effect of captopril on glucose tolerance in inactin-anaesthetised SHRs. Captopril 
(2.3pmol.Kg"', iv) was administered at t=60 minutes. Symbols are: O - control (n=5), or #  -
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Figure R 7. Effect of enalaprilat on glucose tolerance in inactin-anaesthetised SHRs Enalaprilat 
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Figure R 8 . Effect of lisinopril on glucose tolerance in inactin-anaesthetised SHRs Lisinopril 














Figure R 9. Effect of chronic captopril treatment on glucose tolerance in inactin-anaesthetised SHRs. 
Captopril (115pmol.Kg"', sc) was administered at 9am and 4pm. Symbols are: O - control (n=4), 
or •  - captopril (n=7).
The  effects of epicaptonr i l  and  L-cysteine on blood pressure a nd  glucose 
tolerance.
Epicaptopril (2.3|imol.Kg~0 iv) was without effect on blood pressure. 
Diastolic blood pressure was 37 ±4mmHg (n=5) both before and after saline 
treatment, and 39 ± lm m H g before epicaptopril treatment compared with 39 ±2mmHg 
( n-5)  after it. L-cysteine (2.3pmol.Kg ', iv) was also without effect on blood 
pressure. While diastolic blood pressure was reduced from 113 -4  to 86 R7mmHg 
(n=5) in controls, the corresponding figures in L-cysteine-treat.ed.rats were .92. ±8 and. 
76 ±5mmHg (n=5) respectively. Tlie difference in blood pressure reduction was not 
statistically significant.
Epicaptopril was used to determine whether the thiol group on captopril might
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have any activity. A comparison of the post-treatment IVGTTs shows that the two 
curves are different (P<0.01 by ANOVAR), but no two points differ significantly 
(figure R 10). It should be noted that this experiment was carried out using hypnorm 
cocktail anaesthesia rather than inactin. This explains why the initial plasma glucose 
concentrations appear to be high, and may bring into doubt the validity of this result 
compared with the rest o f the results.
L-cysteine, a compound with no known ACE inhibitory activity, is also a thiol- 
carrying compound. However, in contrast to the results obtained using epicaptopril, 
L-cysteine did not have any statistically significant effect upon glucose tolerance 
(figure R 11).
The effect of losartan on blood pressure and elucose tolerance.
Losartan is a recently developed non-peptide antagonist o f angiotensin II type 
1 receptors (Chiu et al., 1990). It was assessed in the same way as the other drugs 
which interfere with the activity o f the RAAS. The dose given (21.7iLimol.Kg'1, iv) 
had previously been shown to cause a 500-fold shift to the right of the A ll pressor 
dose:response curve (figure R 12). In this experiment the dose of losartan given 
significantly worsened glucose tolerance (P<0.01 by ANOVAR), and the peak glucose 
concentration after treatment was significantly higher than in controls (figure R 13).
Losartan did not cause a significant reduction in any aspect of blood pressure. 
This was as a result of one animal responding to the drug with an increase in diastolic 
blood pressure o f 25mmHg. The mean change for the other five animals was -59 
± 13mmHg (range -102 to -25mmHg). If this rogue rat is removed, then the fall in 
diastolic blood pressure is statistically significant in losartan-treated animals (-59 
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Figure R 10. Effect of epicaptopril on glucose tolerance in inactin-anaesthetised SHRs. Epicaptopril 
( lA gm ol.K g'1, iv) was administered at t=55minutes. Symbols are: O - control (n=5), or •
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Figure R 11 . Effect of L-cysteine on glucose tolerance in inactin-anaesthetised SHRs. L-cysteine 
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. Effect of losartan (21 Tpmol.Kg'1, iv) on pressor responses of diastolic blood pressure 
n II (iv) in inactin-anaesthetised SHRs. Symbols are: O - control dose:response curve 
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Figure R 13. Effect of losartan on glucose tolerance in inactin-anaesthetised SHRs Losartan 
(21.7p.mol.Kg'1, iv) was administered at t=33 minutes. Symbols are O - control (n=6 ), or •  - 
losartan (n=6 ). The post-treatment curves are statistically significantly different (P<0.01 by 
ANOVAR) * P<0.05, by ANOVAR and post hoc Studentised range test, compared with control at 
the same time point
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In vitro results: hemidiaphragms.
Insulin concentration:effect curves.
Figure R 14 shows the effect of differing concentrations of insulin (lOpU - lOmU 
(SHRs) or lOOmU.ml"1 (Wistar rats)) on glucose uptake in both SHR and Wistar rat 
hemidiaphragms. Uptake was significantly stimulated at a concentration o f lOOpU. 
ml-1 in diaphragms from both strains of rat (n=4, P<0.05). There was no significant 
difference between the rat strains in the ability of insulin to stimulate uptake either, 
regarding total uptake after two hours, or ED50 (approximately 240pU.mH in 
hemidiaphragms in either strain).
The effect of captopril on glucose uptake by Wistar rat and SHR  
hemidiaphragms.
Captopril was largely without effect on glucose uptake under either control or 
insulin- stimulated conditions.
In SHR hemidiaphragms the only effect of captopril was observed at a concentration 
of captopril o f 10pM when hemidiaphragms were stimulated with ImU.ml' 1 insulin. 
In this case, glucose uptake was significantly reduced by captopril (P<0.01) (figure R 
15, B). The other concentrations of the drug tested, at either high (ImU.ml"1) or low 
(lOpU.mH) concentrations of insulin, were without effect (figure R15, A, C, D).
Likewise, captopril (lOpM) had no effect on insulin-stimulated (lOpU.ml-1 or 
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Figure R 14. Time course of insulin-stimulated glucose uptake in Wistar rat (panel A) and SHR 
(panel B) hemidiaphragms. Symbols are: O - no insulin (n=4). •  - lOpU ml-' insulin (n=4); V - 
lOOpU.ml-i insulin (n=4). ▼ - ImU.mH insulin (Wistar rats n=4. SHRs n=6 T □  - lOmU.mH 
insulin (Wistar rats n=3, SHRs n=4), ■  - lOOmU.ml-' insulin (n=4. Wistar rats only) Significant 
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Symbols are: O - control (n=6 ), or #  - captopril ( n - 6 ). Glucose uptake was less in treated tissues 
than in controls in the experiment represented by graph B (P<0.01 by ANOVAR)
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Figure R 16. Effect of captopril (10pM) on insulin-stimulated (10pU.ml-> (A) or ImUml-i (B)) 
glucose uptake uptake in Wistar hemidiaphragms. Symbols are: O - control (m=6 ), or #  - captopril 
(n=6 ).
In vivo results.
Investigations of associations between plasma glucose control  a nd  plasma 
potassium ion control .
ITese studies were earned out to determine whether the observations o f  Kim 
et cii. (1991). namely that aldosterone levels in SHRs are abnormally high, have any 
functional significance for control o f  plasma K* and glucose concentrations in the 
SHR.
The studies were undertaken in two parts. The first was the observation o f  
plasma K+ concentration during manipulation o f  glucose lev els, and the second was 
the monitoring o f  glucose changes in response to attempts to manipulate K1 
concentration.
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In inactin-anaesthetised rats the mean plasma K+ concentrations were 
3.08±0.16 (n=9) and 3.08±0.13mM (n=l 1) for Wistar rats and SHRs respectively.
Glucose administration (1.39mmol.Kg-1, iv) did not have any statistically 
significant effect on plasma K+ concentration (figure R 17). The ACE inhibitor 
lisinopril (275nmol.Kg_1, iv) was unable to influence this lack of response to glucose 
administration (figure R 18). It must be noted, however, that when two IVGTTs were 
performed in the same rat (figure R 18), although no change in plasma K+ 
concentration was observed during the IVGTTs, the basal plasma K+ levels were 
significantly higher at the beginning of the second test than at the beginning of the first 
(P<0.01 in control group, P<0.05 in lisinopril group).
Chronic treatment of SHRs with an ACE inhibitor (captopril, 230pmol.Kg-i 
.day-i for 14 days) or saline appears to cause a response in plasma K+ concentration 
different from that seen in naive animals. In both control (n=4) and treated animals 
(n=7) glucose tolerance tests had an effect on plasma K+ concentration over time 
(P<0.01), this effect being a transient lowering of K+ concentration. Captopril 
accentuated this lowering effect. After 10 minutes plasma K+ concentration was not 
different from initial values in controls, whereas that in treated animals was 
significantly lower than in control animals (figure R 19).
The attempts to manipulate plasma K+ concentration met with partial success. 
In animals given the Na+/K+ ATPase-stimulating drug aldosterone (1.39nmol.Kg-1, 
iv), the plasma K+ concentration gradually rose from a mean of 3.35mM to 5.1mM at 
t=140 minutes in the two strains o f rat (figure R 20, A). This gradual upward trend in 
plasma K+ concentration became a statistically significant increase at t= l 00 minutes 
and this level of significance remained or increased for the rest of the experiment. 
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Figure R 17. Effect of glucose administration (1 .39mol.Kg'' iv, at t=0) on plasma KT concentration 
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Figure R 18. Effect of lisinopril on plasma K+ concentration during IVGTT in inactin-anaesthetised 
SHRs. Lisinopril (275nmol.Kg'', iv) was administered at f=33 minutes. Symbols are: O - control 
(11=6 ). or •  - lisinopril (n=5). * P<0.05, ** P<0.01 compared with t=0 in the same strain.
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w ith  respect to plasm a K+ concentration.
Plasma glucose concentration was significantly higher in the SHR group 
(P<0.01) than in the Wistar rat group over the course of the experiment. Aldosterone 
did not affect the plasma glucose concentration in SHRs, but did, after about an hour's 
lag, seem to reduce it in the Wistar group. This reduction did not reach statistical 
significance compared with initial plasma glucose concentration in the Wistar rats, but 
it did increase the frequency and level of significance of the difference between Wistar 
rats and SHRs (figure R 20, B).






















Figure R 19. Effect of chronic captopril treatment (230umol.K.g"1 .day' 1 for 14 daysi on 
plasma K+ concentration during 1VGTT in inactin-anaesthetised SHRs Symbols are: O - control
(n=4), or •  - captopril (n=7) The curves are different, P<0.01 (by ANOVAR). ** P<0.01 by the 
post hoc Studentised range test.
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The experiment was originally continued for another 40 minutes, but after 
about 2 hours 20 minutes the state of health of some of the animals was highly 
suspect. It should also be noted that, although the SHRs used in this experiment were 
o f hypertensive blood stock (their parents were bought from Charles River Ltd.), their 
initial blood pressures were not statistically significantly higher than those o f the 
Wistar rats (92 ±12mmHg diastolic in SHRs (n=4) compared with 93 ±14mmHg in 
Wistar rats (n=6)).
The opposite manipulation of plasma K+ concentration, with the Na+/K+ 
ATPase antagonist canrenoate K+, had a similar effect on plasma K+ concentration as 
administration o f aldosterone. In both strains K+ concentration rose gradually 
throughout the experiment, this being from 2.9 ±0.2 to 3.7 ±0.3mM in Wistar rats, and
3.0 ±0.1 to 4.4 ±0.6mM in SHRs at t=180 minutes (figure R 21, A). The increase in 
plasma K+ concentration, compared with t=0 in the same strain, became statistically 
significant at t=140 minutes in Wistar rats (P<0.05), and at t= 120 minutes in SHRs 
(P<0.05). The final difference was statistically significant (P<0.01). The plasma K+ 
concentration was statistically significantly higher in the SHR group (P<0.01 by 
ANOVAR).
ANOVAR indicated a significant difference between the two strains of rat 
(P<0.01) for plasma glucose concentration (figure R 21, B). ANOVAR also indicated 
an interaction of time with strain of rat, implying that the apparent transient increase in 
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Figure R 20. Effect of aldosterone on plasma K+ concentration (A), and plasma glucose 
concentration (B) in inactin-anaesthetised Wistar rats and SHRs. Aldosterone (1 BOnmol.Kg'1, iv) 
was administered at f=22 minutes. Symbols are: O - Wistar rats (n=4i. or •  - SHRs (n--5)
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Figure R 21. E ffect  o f  c a n r e n o a te  KT o n  p la s m a  KT c o n c e n tr a t io n  ( A) ,  a n d  p l a s m a  g l u c o s e  
c o n c e n t r a t io n  ( B )  in i n a c t in - a n a e s t h e t i s e d  W is ta r  rats a n d  S H R s .  C a n r e n o a te  ( 7 5 p . m o l . l v g ' 1. i v > 
w a s  a d m in i s t e r e d  at 1=22 m in u te s .  S y m b o l s  are: O - W is ta r  rats ( n = 6 .  e x c e p t  w h e r e  in d ic a te d ) ,
or •  - S H R s  ( n = 5 ,  e x c e p t  w h e r e  in d ic a te d ) .  P la s m a  g l u c o s e  c o n c e n tr a t io n  w a s  d i f f e r e n t  in  the  tw o  
s tra in s  ( P < 0 . 0 1 ,  by  A N O V A R ) .  * P < 0 . 0 5 ,  **  P < 0 .0 1  by  A N O V A R  an d  post  h o c  S l u d e n t i s e d  r a n g e  
test , c o m p a r e d  w ith  W ista r  rats + P < 0 . 0 5 ,  + +  P < 0 . 0 1 ,  by A N O V A R  a n d  post  h o c  S tu d e n t i s e d  ran ge  
test ,  c o m p a r e d  w ith  t = 0  in th e  s a m e  strain .
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As in the previous experiment, the SHR group did not have a statistically 
higher initial diastolic blood pressure than the Wistar group (106 ±7mmHg (n=5) vs. 
89 ±8mmHg (n=6), respectively). While blood pressure was significantly lower in 
both groups at t= 181 minutes (the end of the experiment) than at t=19 minutes 
(immediately before the canrenoate K+ administration) (87 ±7 (n=6) and 52 ±5 tnniHg 
(n=5) in Wistar rats, respectively, and 90 ±7 (n=5) and 35 ±8mmHg (n=4) in SHRs, 






In recent years the idea that insulin resistance may be a cause of, or at least be 
closely linked to, essential hypertension has become a popular topic for investigation. 
Much of the evidence to support this hypothesis has come from in vivo work with 
patients suffering from type 2 diabetes or obesity (e.g. Modan et al., 1985) or from in 
vitro work with tissues from similar patients (Kashiwagi et al., 1983). Some evidence 
has also come from studies of essential hypertensives (Ferrannini et al., 1987). 
Likewise, animal work has been forthcoming which supports the human data both in 
vivo (Mondon and Reaven, 1988) and in vitro (Reaven et al., 1989).
The work in this project stemmed from these findings, from the several reports 
that ACE inhibitors ameliorate insulin sensitivity in man (e.g. Pollare et al., 1989), and 
from preliminary findings within the Pharmacology Group at the University of Bath 
showing that captopril also improved glucose tolerance in SHRs.
The approach, therefore, was to establish the SHR as a viable model of insulin 
resistance, to characterise its normal response in an IVGTT, and then to use it to test 
the efficacy of several ACE inhibitors in reducing glucose intolerance in the SHR. An 
attempt was then made to explain the actions o f captopril. An in vitro assay was also 
set up to test the insulin responses o f skeletal muscle under more rigidly defined 
conditions, and to test the effect o f captopril on insulin-stimulated glucose uptake.
Having been unable to demonstrate substantial effects o f the drugs tested, it 
was decided to look at the interplay between plasma glucose concentration and plasma 
K+ concentration under various conditions since a number of papers, in particular that 
of Modan and colleagues (1985), have proposed that over-stimulation of Na+/K+ 
ATPase due to hyperinsulinaemia might be one route to essential hypertension. Two
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drugs were therefore used to try to manipulate the plasma K+ concentration and 
monitor plasma glucose concentration concurrently.
In vivo.
Blood Pressures.
As was stated previously, the blood pressure values depicted in figure R 1 
were typical of the rats of each strain. The reason for the low blood pressures of the 
SHRs in the final two experiments (the assessments of aldosterone and canrenoate K+ 
action) is unknown. The rats used in these experiments were the first offspring of a 
new colony of hypertensive stock which had just been bought in by the animal unit at 
the University of Bath. Their pedigree should therefore be assured, and there was no 
readily apparent reason for the low blood pressures recorded in these animals. The 
results o f the last two experiments will therefore be discussed as if the SHR groups did 
have significantly higher blood pressures than their respective Wistar rat control 
groups, although it will be borne in mind that the results may not be as meaningful as 
they appear.
Anaesthetics.
The principal criteria upon which the choice of anaesthetic was based were the 
reliability of induction and maintenance o f anaesthesia, which combine to determine 
the ease of use, and the effects o f the anaesthetic on the system under investigation.
With these factors in mind both urethane and hypnorm cocktail were assessed. 
Although urethane was theoretically the easier to use (it should not need "topping 
up"), it failed to induce anaesthesia reliably, and, as can be seen in figure M 1, plasma
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glucose concentration gradually tailed off during the experiment. Hypnorm cocktail, 
while also being unrehable in induction of anaesthesia, especially in SHRs, and 
requiring "topping up" throughout the experiment, did have the advantage of 
maintaining a relatively steady plasma glucose concentration. Consequently, hypnorm 
cocktail was chosen as the anaesthetic for the main studies. After a period of time, 
during which hypnorm cocktail appeared more and more to be losing efficacy, inactin 
became available. This proved to be a much better drug, on all counts, than hypnorm 
cocktail. It was not really known at the time how hypnorm cocktail might affect 
plasma glucose control, except that it did not appear to have a time dependent effect 
o f its own (figure M 2). Hypnorm cocktail contains a component which is an a  
adrenoceptor antagonist (Kingsbury, PhD thesis, 1989), which tended to lower blood 
pressure, therefore making it very difficult to show that SHRs were actually 
hypertensive. Inactin, on the other hand, did not have this drawback. In a study by 
Hindlycke and Jansson (1992) on the suitability of various anaesthetics for glucose 
tolerance and pancreatic blood flow experiments, it was one of the two drugs 
recommended for such use because of its lack of effect on these two parameters. 
Consequently, inactin was used as the anaesthetic of choice from then on.
The reason for the difference between basal plasma glucose concentrations in 
hypnorm cocktail- and inactin-anaesthetised rats is unknown, but might relate to the 
depth of anaesthesia. An animal which is able intermittently to feel pain (as a result of 
partial recovery of consciousness) will probably respond to the stress by releasing 
hormones such as corticosteroids and catecholamines into its blood. The general 
effects of these are to prime the body for action, the classic "fight or flight" response, 
which include a major component o f gluconeogenesis driven by glucocorticoid and 
adrenaline stimulation of peripheral tissues and growth hormone stimulation of the 
liver (Herd, 1984). This process could therefore account for the difference in plasma
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glucose concentrations.
Evidence for insulin resistance in SHRs.
The result of the analysis o f blood from freshly sacrificed rats suggests that 
plasma glucose concentration in SHRs is higher than in Wistar rats. When combined 
with the data comparing basal plasma glucose concentration in SHRs and Wistar rats 
over two hours (figure M 2), and the initial concentration in the experiment comparing 
glucose tolerance in the two strains (figure R 3, A), both of which show significant 
differences, it is clear that there is more glucose in the blood o f SHRs under basal 
conditions. The difference between the analysis o f blood from freshly killed rats and 
the plasma glucose levels obtained in anaesthetised rats is probably accounted for by 
the action of the anaesthetic which would depress plasma glucose concentration, and 
by the necessary handling of the rats immediately prior to killing them which would, to 
some degree, stress them.
Glucose tolerance in SHRs, however, is difficult to assess. Although 
administration of the glucose load caused a greater increase in plasma glucose 
concentration than in Wistar rats, the SHRs actually seemed more competent at 
removing the glucose than did the Wistar rats. Thus at the end of the glucose 
tolerance test (t=30 minutes) plasma glucose concentration was back to basal levels in 
SHRs, but still significantly higher than basal in Wistar rats. As a result, the area 
under the glucose extinction curve above the basal glucose value was similar in both 
types o f rat. This may have been as a result o f the insulin concentration in SHRs, 
which was significantly higher than in Wistar rats at t=2 (P<0.05), 5 and 10 minutes 
(P<0.01, figure R 3, B). The area under the insulin response curve was also greater in 
SHRs, but this was not statistically significant. It is therefore somewhat difficult to
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draw firm conclusions about the insulin sensitivity of SHRs. The higher basal 
concentrations o f plasma glucose in SHRs combined with normal basal plasma insulin 
could suggest insulin resistance, but could also result from one or more of several 
other mechanisms. The most important of these is the possibility that there is an 
excess of hormones which raise plasma glucose concentration. Glucagon is the most 
obvious candidate, and it is interesting that hyperglucagonaemia is present in type 2 
diabetic patients (Lefebvre, 1991). An overstimulation of glucagon-mediated 
processes (for example stimulation o f glycogenolysis, gluconeogenesis and lipolysis, 
and inhibition o f glycogen synthesis) could well account for the raised basal plasma 
glucose concentration seen in these studies. Adrenaline is another hormone which has 
glucagon-lke properties. In particular it is able to inhibit glycogen synthesis in skeletal 
muscle (Christopher et al., 1992) and stimulate glucose production by the liver. 
Plasma catecholamine levies are generally increased in borderline essential 
hypertensives (Julius, 1991) and, like an excess o f glucagon, this has the potential for 
explaining some or all o f the raised basal plasma glucose concentration in the SHRs. 
Glucocorticoids are a third group with gluconeogenic properties. Other hormones, for 
example glucagon-like peptide 1 and cholecystokinin, are released from the gut during 
digestion and absorption of food, and these have the potential to raise plasma glucose 
indirectly by stimulating the secretion of glucagon (Dupre, 1991).
It cannot be said that the animals are glucose intolerant because the areas 
under the glucose extinction curves are similar. This seems to be as a result of 
hyperinsulinaemia during the glucose tolerance test compensating for the insulin 
resistance. The apparent extra sensitivity to insulin infrision in the SHRs confuses this 
scenario. However, assuming that the SHRs are insulin resistant, one might explain 
the phenomenon thus: since SHRs are frequently exposed to hyperinsulinaemia they 
may down-regulate their receptors more slowly than Wistar rats. The pancreas
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normally releases insulin in small pulses which prevents insulin receptor down- 
regulation (Ward et al., 1990). Therefore a prolonged infusion of insulin might be 
expected to have a greater effect, in terms of receptor down-regulation, in Wistar rats. 
If this is true then the results are more a product of the way in which the insulin was 
administered than of innate insulin sensitivity in the two strains of animal. 
Alternatively, one can hypothesise that because insulin has a longer half-life in SHRs 
than in normotensive rats (Mondon and Reaven, 1988), the plasma insulin 
concentration remained elevated for longer in the SHRs, and this would explain the 
apparently greater effect o f the insulin infusion. This latter hypothesis seems the more 
credible, and therefore implies that the SHRs were not insulin resistant.
The results of the present studies support most of the recently published 
findings. Gaboury and colleagues (1991) demonstrated evidence that WKY rats are,in 
fact, more insulin resistant than SHRs during both IVGTTs and oral glucose tolerance 
tests. Likewise, both glucose disposal and glycogen synthesis were shown to be 
elevated in SHRs compared with WKY rats (Frontoni et al., 1992). These reports 
imply that SHRs are not insulin resistant, a conclusion which is backed up by the 
present studies. The earher data which seemed to support the idea that SHRs are 
insulin resistant (e.g. Yamori et al., 1978; Mondon and Reaven, 1988) were gathered 
using less sophisticated techniques than the later evidence. The most recent report, 
however, which also used the insulin clamp technique, did find a very significant 
correlation of plasma insulin concentration with glucose disposal rate (Rao, 1993).
The SHR has long been regarded as a good model of hypertension, and 
probably the best available. Indeed, Trippodo and Frohlich (1981) stated that "several 
expert panels have reported that the SHR is an excellent model of experimental 
hypertension that could serve as a counterpart for clinical essential hypertension". The 
similarities between essential hypertension in man and hypertension in the SHR are
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manifold. Both types of hypertension are influenced by two or three principle genetic 
loci, on top of which the environment also exerts an influence. In both man and the 
rat, blood pressure can be seen to be raised at an early age (Trippodo and Frohlich, 
1981). Increased total peripheral resistance and cardiac output is a feature common to 
both species, as are hypertrophy of resistance vessels and the heart (Komer et al., 
1991) and the same vessels show a raised contractile response to a wide range of 
agonists (Mulvany et al., 1978). Like the human situation (Trippodo and Frohlich, 
1981), plasma catecholamines have been shown to be elevated in SHRs (Frontoni et 
al., 1992). Renal function is also similar in the two species (Trippodo and Frohlich, 
1981). For these and many other reasons, the SHR has been held in high regard as a 
model of hypertension for many years. However, in view of the present studies and 
those of other workers, it is probably not a good representation of the insulin 
resistance which is frequently found in human essential hypertensives.
Data obtained in experiments using patients with essential hypertension or type 
2 diabetes tend to be more clear-cut. For example, there is usually a more defined (in 
terms of statistical significance) separation of glucose clearance curves in essential 
hypertensives and normotensives (Ferrannini et al., 1987, Pollare et al., 1989) 
compared with that between SHRs and Wistar rats.
Drug effects on blood pressure and glucose tolerance.
Captopril, enalaprilat and lisinopril.
The fact that captopril (2.3pmol.Kg'1) failed to cause a significant reduction in 
diastolic blood pressure in SHRs was surprising, especially in view of the 
demonstration by Muller and colleagues (1990) that 280nmol.Kg_1 captopril (iv) 
caused an almost maximal increase in regional vascular conductance in conscious,
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water-replete Brattleboro rats, and a ten-fold higher dose caused an almost maximal 
reduction in mean blood pressure in these same rats. 2.3pmol.Kg"1 captopril, 
assuming a blood volume of approximately 20ml in a 300g rat, would give a blood 
concentration of the drug of approximately 115pM, if it were administered 
intravenously. Many studies, besides that of Muller and co-workers (1990), have 
shown effective blockade of ACE, or secondary consequences of its blockade, at 
lower concentrations than this estimate. For example, captopril at lpM  and lOpM 
caused a significant increase in the spontaneous production of 6-keto-PGFla by 
Sprague-Dawley rat aortae in vitro (Hoffman et al., 1990), and after an intravenous 
dose of dbOnmol.Kg' 1 captopril pressor responses to lpg.Kg' 1 Al (iv) were reduced 
to 32% of control (pre-captopril) values (Drummer and Kourtis, 1988). It remains 
unclear, therefore, why blood pressure was not reduced by the dose of captopril used 
in this study. One reason, under normal circumstances (normal being when captopril 
does reduce blood pressure), for the present finding is that the measurements were 
taken half an hour after captopril administration. The time course of blood pressure 
after captopril administration in the studies of Drummer and Kourtis (1988) shows 
that both systolic and diastolic blood pressure had nearly recovered to pre-captopril 
levels 24 minutes after the drug was given, having shown a transient reduction which 
peaked 30 seconds after injection. The rats used in the present experiments did not 
show this transient reduction in pressure at all. It may in the end be a futile exercise to 
attempt to explain why blood pressure did not fall. It has been noted that there is no 
correlation between the antihypertensive effect of ACE inhibitors and the ability of 
ACE inhibitors to inhibit the pressor effect of Al in rats (Sweet et al., 1981). 
Therefore this result does not necessarily mean that ACE was not effectively inhibited 
by this dose of captopril. Indeed the previously quoted research (Drummer and 
Kourtis, 1988; Hoffman et al., 1990; Muller et al., 1990) strongly suggests that
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2.3jimol.Kg"1 captopril is more than adequate to provide a very effective block of the 
enzyme. This is also borne out by the results obtained with lisinopril.
Lisinopril (275nmol.Kg_1, iv) was shown to cause a 100-fold shift to the right 
of the Al pressor dose:response curve in SHRs (figure R 5). This activity is at the 
same order of concentration in the blood as that used by Hoffman and co-workers 
(1990) to cause a significant increase in the amount of 6-keto-PGFlcx spontaneously 
released by rat aorta in vitro (of the order of lOpM). However, like captopril, 
lisinopril failed to cause a significant reduction in blood pressure. This is further 
evidence in favour of the findings of Sweet and associates (1981), and strengthens the 
argument that a failure to reduce blood pressure probably has no meaning with respect 
to inhibition of ACE by the same drug.
In contrast with the foregoing results, enalaprilat (lJpm oL K g '1, iv) did cause 
a significant reduction in systolic blood pressure, although the fall in diastolic blood 
pressure was not statistically significant. When a dose of ISOnmol.Kg' 1 (iv) was used 
in conscious, water-replete Brattleboro rats an almost maximal increase in regional 
blood flow and reduction in mean blood pressure was observed (Muller et al., 1990). 
The ten-fold greater dose used here must, therefore, be at or very near to a maximally 
effective dose.
It is therefore apparent that acute administration of an ACE inhibitor has 
separate effects on blood pressure and ACE inhibition, with ACE inhibition occurring 
at doses which have no significant influence on blood pressure. Effective inhibition of 
ACE does not necessarily lead to a fall in blood pressure, and correspondingly, a 
failure of a drug to reduce blood pressure does not mean that ACE is uninhibited.
The results of the IVGTTs require careful consideration. Captopril 
significantly worsened glucose tolerance in SHRs (figure R 6), whereas enalaprilat and
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lisinopril were without effect. The result with captopril was particularly surprising 
since several reports suggest that ACE inhibitors are able to improve glucose tolerance 
in man (Pollare et al., 1989; Torlone et al., 1991) and the most negative findings only 
suggest a lack of any activity of certain ACE inhibitors (captopril - Shionoiri et al., 
1987; ramipril - Kiienberg et al., 1990; lisinopril - Shionoiri et al., 1990).
The varying data for captopril, enalaprilat and lisinopril work very well 
together in trying to explain the action of captopril. Since lisinopril inhibited ACE 
without affecting blood pressure, it seems that ACE inhibition per se is not responsible 
for worsening glucose tolerance. This is supported by the fact that captopril probably 
blocked ACE but also did not affect blood pressure. The lack of activity of enalaprilat 
on glucose tolerance, even though it reduced blood pressure (and presumably inhibited 
ACE), demonstrates that a reduction in blood pressure could not be the cause of 
captopril's activity either. This leaves two main possibilities for the mode of action of 
captopril. The first is that its action on glucose tolerance is not ACE-related and may 
be caused by the presence o f the thiol group on the molecule. This will be discussed in 
the next section. The second possibility is that captopril's properties are related to an 
ability to inhibit a specific isomer of ACE which is not susceptible to enalaprilat or 
lisinopril. A return to this topic will be made later.
It is possibly unrealistic, however, to expect an acute dose of an ACE inhibitor 
to have much effect on glucose metabolism because the vast majority of published 
work has compared indices of glucose and insulin metabolism in chronically treated 
patients (Shionoiri et al., 1987, 1990; Pollare et al., 1989; Torlone et a t ,  1991). 
Therefore captopril was given to a group of SHRs for two weeks. In this experiment 
diastolic blood pressure was significantly lower in the captopril-treated group after 
two weeks, but even so, glucose tolerance was unchanged.
The fact that blood pressure was reduced by chronic administration of 
captopril demonstrates that there was sufficient time for the treatment to affect a 
chronic condition, and implies that if captopril were to affect glucose tolerance it had 
adequate opportunity to do so. It cannot be ruled out, though, that the period of 
treatment was not long enough. One can imagine, for example, that changes in blood 
pressure and glucose tolerance might occur at different rates. Nevertheless, 
experiments investigating the chronic effects of ACE inhibitors on blood pressure have 
shown that four weeks' treatment (Sm g.K g'fday1 perindopril) in rats at a similar age 
to the ones in these experiments (6-8 weeks old) reduces blood pressure long term 
(Harrapp et al., 1990). This also suggests that one ought to see an effect, if one is 
going to occur, at two weeks, even if it is not permanent at that stage.
These results challenge those published by other authors. Although some 
reports mention a lack o f effect o f ACE inhibitors (e.g. Shionoiri et al., 1987, 
Kiienburg et al., 1990), others have shown an improvement in insulin resistance 
(Pollare et al., 1989, Torlone et al., 1991). The finding that, if anything, captopril 
worsens glucose tolerance in SHRs appears to be a new one, and it challenges the 
establishment. In the long term, however, a more clinically relevant situation, 
captopril had no effect, in accord with some of the published observations.
Epicaptopril and L-cvsteine.
Although in a clinically important situation captopril does not seem to have 
any effect on glucose tolerance, it was decided to continue with this series of studies 
because it was possible that captopril might be having two opposing actions which 
result in no overall activity. In addition, an attempt needed to be made to explain why 
captopril worsened glucose tolerance in the acute phase. With this in mind, and results
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from preliminary experiments which hinted at the involvement of captopril's thiol 
moiety, it was decided to investigate the possible role of this substituent in captopril's 
actions.
Epicaptopril was therefore chosen, being the 100-fold less active enantiomer of 
captopril, and given at the same dose as captopril to ensure an equivalent dose of thiol. 
Like captopril, epicaptopril significantly worsened glucose tolerance, indeed implying 
a role for the thiol group. It is not, however, totally without ACE inhibitory activity, 
and in order to avoid this possible confounding factor, L-cysteine was also tested at 
the same dose. In contrast to epicaptopril, L-cysteine did not affect glucose tolerance. 
This brings up the intriguing possibility that the active component of captopril (with 
respect to glucose tolerance) may not be the thiol group, but rather the epicaptopril 
which is also present (captopril is a racemic mixture of 50% active captopril and 50% 
epicaptopril). If epicaptopril were the active constituent, then it might be working in 
one of two ways. (Since L-cysteine did not affect glucose tolerance, the possibility of 
the involvement of the thiol group seems to have been ruled out.) These are that 
epicaptopril could have a specific activity unrelated to ACE inhibition or All, or that it 
could be acting as an ACE inhibitor (even though it is 100-fold less potent than its 
active stereoisomer) at a site which is not susceptible to enalaprilat or lisinopril.
Both of these drugs (epicaptopril and L-cysteine) did not significantly affect 
any blood pressure parameter which leads to the conclusion that the thiol group on 
captopril in no way affects blood pressure. This, combined with the following section, 
further suggests that the thiol group on captopril does not have any activity relevant to 
the current investigations. It must be remembered, however, that the assessment of 
the efficacy of epicaptopril was undertaken using hypnorm cocktail anaesthesia. Since 
this as been shown to contain an element which is an a  adrenoceptor antagonist 
(Kingsbury, PhD thesis, 1989) one cannot be certain that it will not affect glucose
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tolerance, a  agonists tend to inhibit the release of insulin. Therefore one would 
expect that an antagonist would have the opposite action. Assuming that this is the 
case, the predicted result o f the experiment would be an improvement in glucose 
tolerance because the longer exposure of the animals to the anaesthetic by the start of 
the second IVGTT ought to induce a higher plasma insulin concentration during the 
second IVGTT. This implies that the epicaptopril effect on glucose tolerance might 
have been larger with a different anaesthetic. If, on the other hand, the argument is 
taken a step further, then the higher plasma insulin concentration may have caused 
insulin receptor down-regulation by the start of the second IVGTT and actually, 
therefore, worsened glucose tolerance. The fact that worsened glucose tolerance is 
the observed result hints that this extension of the hypothesis might be vahd. 
However, it is probably much safer to accept the result at face value but, as a result of 
these doubts, accord them rather less weight when considering the results as a whole. 
Indeed it seems unlikely that epicaptopril is acting as an ACE inhibitor given the large 
difference in activity between it and active captopril, and considering the general lack 
of specificity of ACE inhibitors in general (Vago et al., 1992). This leaves the 
possibility that this drug has a specific activity of its own, which seems less likely than 
it being a potent ACE inhibitor. By a process of elimination, then, it is probable that 
the result with epicaptopril is a spurious one and should be ignored.
Losartan.
The A ll type 1 receptor antagonist losartan was assayed in similar fashion to 
the ACE inhibitors to provide further evidence of the role of All in regulating glucose 
tolerance. The dose used had previously been tested against the A ll pressor response 
to ensure it provided adequate blockade of Ail receptors (figure R 12). Interestingly,
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although previous results had suggested that any action of captopril was probably not 
due to ACE inhibition, losartan had a similar effect to captopril - i.e. it significantly 
worsened glucose tolerance (figure R 13). This suggests that All actually promotes 
glucose tolerance in SHRs.
Perhaps the most likely explanation of the apparently conflicting data lies in 
different isoforms of ACE in different regions of the body. That these exist is a safe 
assumption. A study o f [3H]trandolaprilat binding by Bree and colleagues (1992) 
showed that at least two different forms of ACE exist in Wistar rats - one with two 
active sites, to be found in the brain and lung, and one with only one active site, found 
in the testis. A comprehensive study by Vago and associates (1992) compared binding 
and potency characteristics of thirteen ACE inhibitors in lung and heart samples from 
man and rats. It was notable that some ACE inhibitors did not show any selectivity for 
ACE from a particular sample (lung or heart), but others did. In the former group one 
finds captopril and quinapril, while in the latter one sees enalapril which preferentially 
bound to the lung isoform. Therefore one might expect certain ACE inhibitors to be 
more potent in certain regions o f the body than others. Bearing this in mind, it can be 
hypothesised that captopril is able to inhibit an ACE at a site in the body which is not 
susceptible to enalaprilat and lisinopril. If  losartan also has access to this system, that 
might explain the apparent anomaly. Thus captopril and losartan could inhibit the 
production or action, respectively, of All, which would normally promote glucose 
uptake, at a local site, while lisinopril and enalaprilat are inactive. This conclusion also 





The reasons for choosing the diaphragm as an assay tissue were largely a result 
o f practicality, but also because it has been used in a similar fashion to the present 
studies by others (Kirby and Turner, 1975; Hothersall et al., 1990). The muscle is 
easy to get to and dissect out without greatly damaging the muscle fibres (Hothersall 
et al., 1990), it is thin and easily divided into two, thereby overcoming to a large 
extent the problems of diffusion and availability of control tissues, and it is a good 
example o f red (slow oxidative) muscle. Red muscle has been shown by several 
studies to be the most insulin sensitive of the three types of skeletal muscle in the body 
(Kraegen et al., 1985, James et a l, 1985). Therefore one would expect to see good 
insulin-stimulated glucose uptake in diaphragm, and if insulin resistance is an intrinsic 
property o f muscle, then it ought to occur in red muscle since white (fast glycolytic) 
muscle probably does not have the capacity to reduce its uptake enough to account for 
the reduction in whole body glucose uptake which is seen in insulin resistance. 
Alternative tissues have been used by other investigators. For example, Stace and 
colleagues (1990) used soleus muscle of the rat. The disadvantage o f using this and 
other large muscles is the problem of diffusion of substances into and out of the tissue 
and the damage done to the muscle in removing thin strips (to avoid diffusion 
problems) which is an inevitable consequence.
The insulin concentration:effect relationship in diaphragms from the two 
strains of rat was not significantly different. Both the EC 50 and cumulative glucose 
uptake after two hours are similar in the two strains, suggesting, assuming that the 
Wistar rats are "normal", that there is no evidence from this experiment o f insulin 
resistance in SHRs. The data presented in this experiment are in reasonable
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accordance with published results, which state an ED50 in vivo o f approximately 
150pU.mH in diaphragm of Wistar rats, (Kraegen et al., 1985). One would expect to 
need a higher concentration for the same effect in vitro due to the problems of 
diffusion. Therefore an EC50 of approximately 240pU.ml'1 seems to indicate a viable 
assay set-up. Total stimulation of uptake is a little different, the maximum reported to 
be a ten-fold increase in vivo (Kraegen et a l, 1985) In the present study a two-fold 
increase was achieved. However, this is similar to the 50% increase o f glucose uptake 
stimulated by 0.5mU.ml-1 insulin reported by Hothersall and colleagues (1990). Once 
again, in spite o f the thinness o f the muscle, this was due to diffusion problems, of 
glucose into the muscle in this instance.
The lack of any insulin resistance in isolated diaphragms brings to the fore an 
important point. Assuming that the results of the preliminary in vivo work do indicate 
insulin resistance in SHRs, it appears that insulin resistance is not purely an intrinsic 
property of skeletal muscle. Two explanations spring to mind. The first has been 
proposed in the literature (Lilhoja et al., 1987). These workers found that glucose 
intolerance correlated with both capillary density and fibre type in skeletal muscle in 
man. The less glucose-tolerant a patient was, the greater was the proportion of white 
(fast glycolytic) muscle in a biopsy o f vastus lateralis, and the fewer the capillaries per 
unit of cross sectional area of muscle. Therefore the proportion o f white muscle in 
SHRs may be higher than in Wistar rats, but the difference may not be great enough to 
show in such a small tissue as the rat diaphragm. Additionally, if the capillary density 
were lower in the SHR diaphragm this would be negated by the fact that in the in vitro 
situation all the components of the Krebs' solution diffuse in across the large flat 
surface of the tissue, thus putting muscle from the two strains of rat on an equal 
footing. The second explanation is more tenuous and has little published data to back 
it up directly. It is possible that some nervous or humoral factor makes the muscle
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insulin resistant. What that factor might be is open to debate. A humoral substance is 
probably the favourite since studies like those of Bachmann and co-workers (1991) 
have shown the transmission of hypertension from one organism to another. 
Endogenous digitalis-like substance (EDLS) is a candidate (although it was ruled out 
by Bachmann and colleagues (1991) because their study showed no effect on Na+/K+ 
ATPase). This has been shown to be present in raised concentrations in SHRs 
(Hamlyn and Manunta, 1992), but it is not clear how it might affect glucose uptake. 
Amylin, as discussed in the introduction, is another candidate for such a factor. Since 
this has also been shown to be present in increased quantities in insulin resistant 
patients (Eriksson et a l,  1992) it also warrants further investigation.
The effect of captopril on glucose uptake by Wistar rat and SHR  
hemidiaphragms.
Whether the difference between the in vivo and in vitro situations is primarily 
caused by physical (due to capillary density or muscle composition) or humoral 
factors, captopril is unlikely to be an important modulator o f glucose uptake.
It was only in one experiment that captopril had any influence on glucose 
uptake by the hemidiaphragm, this being when uptake was stimulated with ImU.mk1 
insulin in the presence of lOpM captopril. As was demonstrated in vivo, rather than 
improving glucose uptake, captopril worsened it. This was a little surprising since this 
concentration o f the drug was bracketed, and neither the higher nor the lower 
concentration was able to modify insulin's activity. If one assumes that this was not a 
spurious result, the most prudent explanation is that captopril has two actions in this 
tissue. The first action is to inhibit glucose uptake at a lower concentration than that 
which is needed for its second, uptake promoting activity. The only example of a dual
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action of ACE inhibitors is the differential blocking of two different forms of ACE 
which have different affinities for drugs (Vago et al., 1992). Perhaps a higher 
concentration (e.g. lOOpM) of captopril would have resolved the problem by revealing 
an actual improvement in glucose uptake. Although this would only have been of 
academic interest (such concentrations are too high to be used therapeutically) it might 
have provided an insight into a target for a future generation of drugs.
One point which it is important to draw from these results is that while 
captopril may have some activity, depending on the concentration used, the SHR 
tissues are not insulin resistant in their own right. One must ask the question, 
therefore, whether captopril can actually treat the root cause of insulin resistance in 
vivo. Clearly the results from these studies suggest not, and where other researchers 
have found captopril to be effective in increasing insulin-stimulated glucose uptake 
(Pollare et al., 1989), the current data imply that this is not an action upon the 
fundamental dysfunction in insulin resistance.
The fact that captopril had no effect on insulin-stimulated glucose uptake in all 
but one of the situations tested reinforces the in vivo data from chronically treated 
rats. Indeed, overall these results complement the in vivo data quite well by 
suggesting that captopril may worsen glucose uptake under some circumstances but 
that it is generally inactive.
In vivo.
Investigations of the interaction between plasma glucose and potassium  
concentrations.
The rationale for examining the possible links between plasma glucose and K~ 
concentrations is threefold. Insulin is known to stimulate the Na+/K+ ATPase (Hundal
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et al., 1992) and although it is not clear how alteration of Na+/K+ ATPase activity 
might affect glucose tolerance, it could have an effect on blood pressure. It is also 
known that aldosterone levels are substantially raised in SHRs (approximately four­
fold) compared with Wistar rats, which has obvious implications for plasma K+ control 
(Kim et al., 1991). Finally, it is well documented that K+ supplementation o f the diet 
o f both rats and man is able to reduce blood pressure (Cappuccio and MacGregor, 
1991). It seems unlikely, therefore, that K+ would not be involved in a complete 
explanation o f the pathology of hypertension.
The first evidence from these studies, however, was not promising. The basal 
plasma K+ concentrations were identical in SHRs and Wistar rats. This showed that 
the "set point" for K+ concentration was similar in each strain.
The measurement o f plasma K+ concentration during testing of the effect of 
lisinopril on glucose tolerance revealed that this parameter increased after an IVGTT, 
even though it does not change during it. The reason for this is unknown. Moreover, 
one cannot draw the conclusion that the rise in K+ concentration is different in 
lisinopril-treated animals compared with controls since the spread of values is so great 
in the treated group. It must be concluded, then, that acutely raising plasma 
concentrations o f insulin and glucose had no immediate effect on K+ dynamics. In 
addition, the rise in K+ between the two IVGTTs is not explicable in conventional 
terms (the stimulation o f Na+/K+ ATPase by insulin), since insulin would be expected 
to have the opposite effect from that which was seen.
While acute administration o f glucose may have no effect on K+ control, when 
animals were treated chronically with either captopril or saline, an effect appears to 
have been revealed. A transient lowering of plasma K+ concentration occurred in 
response to glucose administration, which conforms to conventional explanations of
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insulin action. Once again, why this should occur in animals chronically treated with 
saline, but not in previously untreated animals is not readily apparent. One must 
consider that the possibility that the process of injecting the animals twice a day for 
two weeks is in itself sufficient to bring about this change. Assuming this to be the 
case, the most likely explanation o f the effect is that the regular release of stress 
hormones caused by the process o f injection made the animals more sensitive to the 
Na+/K+ ATPase-stimulating abilities of insulin.
Treatment of SHRs with captopril for two weeks did produce the first 
evidence o f these studies that the drug might be able to improve insulin sensitivity. In 
captopril-treated animals, the reduction in plasma K+ lasted longer than in saline- 
treated subjects, thus implying that insulin was having a more prolonged effect than in 
controls. This could be explained in terms of a greater release of insulin from the 
pancreas, but to date all o f the explanations in the literature have rationalised 
captopril's activity in terms of end organ efficacy (e.g. Pollare et a l, 1989). The lack 
of effect of chronic captopril treatment on glucose tolerance suggests that the link 
between K+ and glucose control, if it exists, is not a strong one. However, the 
possibility of a link, however weak, merited further investigation, and the second part 
of this study was carried out.
The dose of aldosterone used was extracted from the literature. Kim and 
colleagues (1991) quoted a plasma value o f 441pg.ml_l in Wistar rats, and 490pg.mH 
in SHRs, while others have reported a value of 11.3pg.ml‘l in Wistar rats (Ando et a l, 
1991). The dose chosen, 1.39nmol.Kg'1, assuming a blood Volume Of approximately 
20ml, would therefore be expected to raise plasma concentration o f the 
mineralocorticoid by between 15- and 70-fold in the first instance. This dose was able 
to increase plasma K+ concentration in both strains o f rat, although there was no 
difference between them. It may have been that the system through which aldosterone
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exerts its effect on plasma K+ was less sensitive than normal in the SHR, but that this 
was overcome by the large dose o f aldosterone given. With more time, a dose 
response curve could have been constructed for each strain, and this question would 
have been resolved. Extrapolating from the results in the previous experiments, 
however, it seems highly likely that no major differences would be seen.
Aldosterone is normally thought of as a compound which promotes Na+ 
absorption and K+ excretion in the kidney (Zannad, 1991). The results obtained in this 
study (the increase of plasma K+ concentration after aldosterone administration) do 
not reflect such an action. The change in K+ levels is probably due to a reduction of 
cellular K+ uptake by skeletal muscle, as seen in vitro by Adler (1970).
The administration of aldosterone provided the first evidence of a connection 
between plasma K+ and glucose concentrations, and that there might be a differential 
response in the two strains of rat. For while plasma glucose concentration in SHRs 
seemed insensitive to aldosterone (Figure R 20, B) this was not the case for Wistar 
rats, where it decreased. There was a lag before the reduction occurred, which tempts 
one of two suggestions. Either aldosterone had a direct, but delayed, effect on 
glucose handling, or the change in plasma K+ concentration, which its administration 
brought about, at some point reached a threshold which then affected glucose 
metabolism. It is not possible to say which of these two possibilities is more likely 
from the data presented here. The difference between the two strains can be explained 
in terms of different thresholds for aldosterone or K+ action. It is not surprising that 
the SHR should be less sensitive to aldosterone than Wistar rats since the 
concentration o f aldosterone increases quite dramatically over time in SHRs, whereas 
it stays relatively constant in Wistar rats (from 441pg.ml_1 at five weeks old to 
317pg.ml_1 at 25 weeks old in Wistar rats, and from 490pg.mH to 1351pg.mW in 
SHRs (Kim et al., 1991)). One would expect such high concentrations of aldosterone
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in SHRs to occur as a result o f resistance to its actions, or to create a resistance by 
down-regulation of receptors or by some other means.
The opposite manipulation, the inhibition of Na+/K+ ATPase as opposed to its 
stimulation, was attempted in order to cover the possibility that the basal 
concentration o f aldosterone might have been stimulating Na+/K+ ATPase at a 
maximal rate in the SHRs, thereby explaining why exogenous aldosterone had no 
effect. Canrenoate K+ had the same general effect on plasma K+ concentration as 
aldosterone (i.e. plasma K+ concentration gradually increased). This similarity of 
effect for oppositely acting drugs was surprising, and tends to suggest that the two 
drugs were acting at different sites in the body. Since canrenoate K+ is very closely 
related to the diuretic spironolactone (it is the primary active metabolite of 
spironolactone) its main action is in the kidney. Inhibition of Na+ resorption in the 
distal tubule of the nephron could, as was observed, gradually raise plasma K+ 
concentration by preventing the concomitant kaliuresis. Any action it might have at 
extra-renal sites would also tend to inhibit the extraction of K+ from the plasma and 
therefore promote a gradual accumulation of K+ in the blood. Unlike aldosterone, 
however, canrenoate K+ caused the plasma K+ concentration to be greater in the SHR 
group than in the Wistar rat group. This implies that the SHR has a constitutively 
more active Na+/K+ ATPase than its Wistar rat counterpart, and the inhibition of this 
by canrenoate K+ had a correspondingly larger effect on plasma K+ concentration than 
in Wistar rats.
The plasma glucose concentrations were also different. The initial 
concentrations were as expected, with that in the SHRs being significantly higher than 
in the Wistar rats. In this experiment it was the Wistar rats which were unaffected by 
the treatment, and the SHRs which responded to canrenoate K+ by increasing the 
plasma glucose concentration. The result of the analysis of variance indicated an
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interaction between time and plasma glucose concentration, suggesting that the 
transient rise in plasma glucose concentration was a real effect. This is in contrast 
with the results of Clausen (1966) who found tha ouabain (which also inhibits Na+/K+ 
ATPase) stimulated production of glycogen in rat diaphragm in vitro, suggesting that 
in vivo this drug ought to increase glucose uptake. It is not known why quite such 
radically different findings should occur in in vitro and in vivo situations. However, 
the present finding complements the aldosterone results, and one can thus propose an 
explanation for the results which demonstrates that variations in plasma K+ 
concentration do affect glucose metabolism. If one supposes that aldosterone, 
through its actions on Na+/K+ ATPase in skeletal muscle, increases glucose uptake 
then the data obtained in these studies suggest two things. The first is that in Wistar 
rats where aldosterone concentration is low, addition of further aldosterone will 
reduce plasma glucose concentration. In contrast, in SHRs, where aldosterone is high, 
aldosterone is already stimulating Na+/K+ ATPase as much as it may, and cannot have 
any additional effect. When canrenoate K+ is administered to SHRs the existing 
promotion of glucose uptake is removed and plasma glucose concentration rises, while 
the same drug in the control animals has little effect because the stimulation of skeletal 
muscle Na+/K+ ATPase by the prevailing aldosterone concentration is negligible.
These results therefore provide indirect evidence that the control o f plasma K+ 
and glucose concentrations are interlinked, possibly through the action o f aldosterone. 
This possibility is supported by a report o f greatly raised plasma aldosterone 
concentrations in SHRs compared with Wistar rats (Kim et al., 1991). The link may 
not be causal, in either direction, but could merely represent the coincidence o f two 
actions o f aldosterone. These experiments do not provide an explanation of insulin 






Taking this study in isolation, one is forced to conclude that the SHR does not 
show many signs of insulin resistance, and that ACE inhibitors do not have the 
potential to improve glucose tolerance. In the context of the available literature, the 
model is probably a not good representation o f the human condition. The effect of 
captopril on insulin resistance has been reported as beneficial or negligible in the 
literature. The finding that in the acutely treated SHR this drug worsens glucose 
tolerance is therefore a new one. The activity does not appear to be a generic one, 
however, since the other ACE inhibitors tested did not have the same effect. It is not 
easy to draw conclusions about the mode of action of captopril. An action o f the thiol 
group is an unlikely explanation of captopril's activity, which leaves a site-specific 
inhibition o f ACE as the most probable cause of its effects on glucose tolerance.
Having failed to demonstrate insulin resistance in the isolated diaphragm of 
SHRs, the most pertinent deduction to be made is that the muscle fibres in this tissue 
are not themselves intrinsically insulin resistant. This is probably the reason for being 
unable to demonstrate substantial insulin resistance in vivo.
There does appear to be a link between plasma K+ concentration and plasma 
glucose concentration. While the set point for plasma K+ concentration is similar in 
the two strains o f rat, the manipulation with aldosterone and canrenoate K+ show that 
stimulation of Na+/K+ ATPase tends to reduce plasma glucose concentration, and that 
the constitutive activation of Na+/K+ ATPase in SHRs is much greater than that in 
Wistar rats. There are grounds, therefore, for examining this link more closely.
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Future work.
For reasons of cost, the only measurements of plasma insulin concentration 
made in vivo were during the establishment of the intravenous glucose tolerance test 
model. Since plasma glucose concentration results from a balance between the insulin 
sensitivity of peripheral tissues and plasma insulin concentration, one needs to know 
both the first and last of these measurements before one can be sure o f the second. 
Therefore to be certain of the effect o f ACE inhibitors on glucose metabolism, one 
would ideally need to repeat the key in vivo experiments (those with captopril, 
epicaptopril, and losartan) incorporating a measurement of insulin at the same time.
The results showing that diaphragm from SHRs is not intrinsically resistant to 
insulin need further investigation. As was hypothesised in the discussion, this could 
mean that an external factor is responsible for creating insulin resistance. It would be 
wise, in the first instance, to find out whether this is representative o f the majority of 
skeletal muscle by using other preparations and determining whether they show any 
resistance. Possible candidates are red (slow glycolytic) and white (fast glycolytic) 
gastrocnemius muscle, and soleus (mixed slow oxidative and slow glycolytic) muscle. 
Assuming that the results are similar to those from the diaphragm, one could then add 
some of the more common blood-borne anti-insulin factors (for example glucagon or 
adrenaline) to the incubation medium to determine whether the muscle is atypically 
sensitive to them. Digitalis and/or ouabain also merit investigation, especially since 
ouabain is thought by some to be EDLS (Blaustein and Hamlyn, 1991).
The final section of the studies described in this thesis relate to the 
interconnection of plasma glucose and K+ control. These experiments appear to show 
that there is a connection. Therefore some investigation of what this might be is in 
order. The major drawback of the studies so far is that they employ only one dose
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each of aldosterone and canrenoate K+. A variety of doses of these drugs ought to be 
tested in a more extensive investigation, using a similar methodology to the one used 
here, to obtain information such as threshold dose, maximum possible effect, and ED50 
of the drugs. It would also be very useful to measure the plasma concentrations of 
aldosterone before experimental intervention, and of aldosterone and canrenoate K+ 
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Comparison of glucose uptake by diaphragm of normotensive and spontaneously hypertensive rats.
D.S.T. Crabbe, P.H. Redfem, B. Woodward, & K.I.Williams, School of Pharmacy and Pharmacology, University of Bath, 
Claverton Down, Bath BA2 7 AY. United Kingdom.
In recent years it has been proposed that insulin resistance may be a cause of hypertension (Reaven, 1988). Soleus muscle of 
patients with type 2 diabetes mellitus, another syndrome of insulin resistance, has been shown to be less responsive to insulin than 
normal muscle (Dohm et al., 1988), and Reaven and colleagues (1989) have demonstrated insulin resistance in adipocytes from 
spontaneously hypertensive rats (SHR). We have shown that SHR are glucose intolerant when compared with Wistar rats and that 
this intolerance is ameliorated by captopril treatment (Crabbe et al., 1991). These factors have led us to compare glucose uptake in 
an in vitro skeletal muscle preparation of SHR and Wistar rats.
We have adapted the method of Kirby and Turner (1975) for measuring glucose uptake by hemidiaphragms from male Wistar rats 
or SHR (both University of Bath strain) weighing 200-250g. Diaphragms were excised, washed in ice cold, glucose-free Krebs- 
Henseleit solution (KHS), and incubated in 3ml of glucose-containing (15mM) KHS in a shaking (150 strokes.min1), heated (37°C) 
water bath for two hours. Each flask already contained appropriate incubation additions to the KHS (lO/xU.mH-lOOmU.ml'1 
human insulin or vehicle) and was gassed with moist 95%02/5%CC>2- 100/xl samples were taken at t=  lOmin, t=20m in, and every 
20min thereafter for subsequent glucose estimation using a colourimetric glucose oxidase assay. A second set of experiments was 
performed to determine the effect of captopril (1-30/iM) on insulin-stimulated (ImU.ml-1) glucose uptake.
Insulin-stimulated glucose uptake by hemidiaphragms between 10 and 120 minutes was concentration-related and linear. There was 
no significant difference between the rates of uptake in the two strains. For example at 100/xU.mH insulin the rate of uptake was 
0.55±0.09^m ol.m in'1g '1 tissue wet weight in Wistar rats and 0.54±0.04^mol.min’1g-1 in SHR (mean ±sem , n=4). Likewise, the 
total insulin-stimulated glucose uptake after two hours was similar (80.76+15.06^imol.min1g 1 in Wistar rats and 
79.04+9.02/im ol.m in'1g’1 in SHR, at 100/xU.mH insulin, n=4). Captopril (l-30^iM) did not alter insulin-induced glucose uptake 
in either strain of rat.
The results show that isolated diaphragm of SHR is not insulin resistant under these conditions. Since it has been demonstrated that 
this same strain of rat is glucose intolerant (Crabbe et al., 1991) it seems that a systemic input is necessary to render the animals 
insulin resistant. Perhaps, therefore, reduced insulin sensitivity in SHR is not purely a defect of insulin signalling, but is dependent 
on other factors. These factors remain obscure, but might include glucagon and other glucose regulating hormones.
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